Welcome ................................................................. p. 3
Keynote Speakers ............................................. p. 4
Lifetime Achievement Award .............................. p. 5
Program ................................................................. p. 6
- Program at Glance . ........................................... p. 6
- Wednesday, November 1 ................................. p. 8
- Thursday, November 2 ................................. p. 9
- Friday, November 3 ........................................ p. 12
- Saturday, November 4 ........................................ p. 15
Poster sessions .......................................................... p. 19
Gold Partners .......................................................... p. 43
General Information .......................... p. 44
Conference Mobile App .................. p. 47
Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

At CTAD 2017 several teams will report the results of their preclinical, Phase II and Phase III trials. This sharing of experiences converges towards a same goal: overcoming the hurdles and speed the development of effective treatments in AD.

Welcome to Boston!

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer’s Therapeutic Research Institute (ATRI)
University of Southern California (USC), San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California San Francisco (UCSF)
USA
Rachelle Doody, MD, PhD  
is the Global Head of Neurodegeneration in Product Development, Neuroscience at Roche Pharmaceutical Company and it US entity, Genentech. She holds a BA in English and MA/PhD in Cognitive Anthropology from Rice University (focus on the brain and language), and did her medical training at Baylor College of Medicine in Houston, Texas.  
Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she had founded and directed the Alzheimer’s Disease and Memory Disorders Center over a period of 27 years.  
In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011. 

John Anthony Hardy, PhD  
is a human geneticist and molecular biologist at the Reta Lila Weston Institute of Neurological Studies at University College London with research interests in neurodegenerative diseases.  
Following his PhD, Hardy did postdoctoral research at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, England and then further postdoctoral work at the Swedish Brain Banlung in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College London in 1985 and initiated genetic studies of Alzheimer’s disease there. He became Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to National Institute on Aging, Bethesda, Maryland, as Chief of the Laboratory of Neurogenetics in 2001. In 2007 he took up the Chair of Molecular Biology of Neurological Disease at the Reta Lila Weston Institute of Neurological Studies, University College London. On November 29, 2015, he was awarded the Breakthrough Prize. 

Reisa A. Sperling, MD, MMSc  
Director, Center for Alzheimer’s Research and Treatment  
Professor of Neurology, Harvard Medical School  
Director of Clinical Research, Memory Disorders Unit, Brigham and Women’s Hospital  
Director, Neuroimaging Program, Massachusetts Alzheimer’s Disease Research Center  
Reisa Sperling MD, MMSc is a neurologist, specializing in dementia and imaging research. Dr. Sperling’s research is focused on the early diagnosis and treatment of Alzheimer’s disease. Her recent work involves the use of functional MRI and PET amyloid imaging to study alterations in brain function during in aging and early Alzheimer’s disease. 
She is the Principal Investigator on multiple NIH and Foundation grants to study the neural basis of memory impairment in MCI and AD, and the relationship of amyloid deposition to memory function. 

Pierre N. Tariot, MD  
Director, Banner Alzheimer’s Institute, Research Professor of Psychiatry, University of Arizona College of Medicine  
Dr. Tariot is Board Certified in Internal Medicine and Psychiatry, with added qualifications in geriatrics. He served as a Fellow at the National Institute of Mental Health and as faculty at the University of Rochester Medical Center. Since 2006, he has been at the Banner Alzheimer’s Institute in Phoenix, where he serves as Director. He has investigated the diagnosis, therapy and prevention of Alzheimer’s disease, and has published over 350 papers on these topics. Together with his colleague, Eric Reiman, he serves as co-director of the Alzheimer’s Prevention Initiative, an NIH-funded international program to study experimental therapies that may delay or even prevent the symptoms of Alzheimer’s in people at high imminent risk. He is a Research Professor of Psychiatry at the University of Arizona College of Medicine. His research affiliations include the NIA, the NIMH, and the Alzheimer’s Association.
Bruno Dubois, MD, PhD

Bruno Dubois is Professor of Neurology at the University Salpêtrière Hospital in Paris. He is Director of the “Institute for Memory and Alzheimer Disease” (IM2A) and of the Research INSERM Unit on “Cognition and Neuroimaging in Brain Diseases” at the ICM at the Salpêtrière Hospital. He is Coordinator of the National Reference Center for “Rare Dementias”; of the National Reference Center for “Young-Onset Alzheimer disease” and of the Center of Excellence for Neurodegenerative Disorders (CoEN) of Paris. He was involved in the elaboration of the Presidential Alzheimer Plan and he is in the Executive Committee of the Plan.

Professor Dubois completed his Neurology residency and a fellowship in Behavioral Neurology at the Salpêtrière hospital. He has published more than 500 peer-reviewed articles on anatomical and biochemical studies on the central cholinergic systems in rodents and humans, on human cognition with special reference to memory, executive functions and frontal lobe behaviors and on biomarkers in neurodegenerative disorders. He was co-chairing the task force on the criteria and guidelines for the diagnosis of Parkinson’s disease dementia under the auspices of the Movement Disorders Society. He leads an international working group of experts on the new criteria for Alzheimer Disease.

Bruno Dubois is member of the Académie Nationale de Médecine. He is “Chevalier de la Légion d’honneur”.

2017 Recipient of the CTAD Lifetime Achievement Award
**CTAD 2017**

**PROGRAM AT GLANCE**

All sessions are held in General Ballroom AB

---

**Wednesday, November 1**

- **4:00 – 4:30 p.m.** Welcome from the Organizing Committee and Presentation of the CtaD Lifetime Achievement Award
- **4:30 – 5:00 p.m.** **Keynote 1** - The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
- **5:00 – 6:00 p.m.** Late Breaking Oral communications
- **6:00 p.m.** End of the Scientific Program
- **6:15 – 8:00 p.m.** Turning Point Documentary
  *Please join filmmaker James Keach for a reception with refreshments*

---

**Thursday, November 2**

- **8:30 – 10:00 a.m.** Oral communications
- **10:00 – 10:30 a.m.** Coffee Break and Poster Session
- **10:30 – 11:30 a.m.** Oral communications
- **11:30 – 12:30 p.m.** **Symposium 1** - CTAD 2017 Statistical Workshop: Estimands and Primary Analyses in AD Clinical Trials
- **12:30 – 1:30 p.m.** Lunch and Poster Session
- **1:30 – 2:30 p.m.** Oral Communications
- **2:30 – 3:00 p.m.** **Keynote 2** - From Academy to Industry: Perspectives for Drug Trials in AD
- **3:00 – 4:00 p.m.** Late Breaking Oral Communications
- **4:00 – 4:30 p.m.** Coffee Break and Poster Session
- **4:30 – 5:30 p.m.** **Symposium 2** EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease
**Friday, November 3**

8:30 – 10:00 a.m.  Oral Communications

10:00 – 10:30 a.m.  Coffee Break and Poster Session

10:30 – 11:00 a.m.  **Keynote 3** - Genetic Aspects In Clinical Trials

11:00 – 12:30 p.m.  Oral Communications

12:30 – 1:30 p.m.  Lunch and Poster Session

1:30 – 2:30 p.m.  Symposium 3
    Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin

2:30 – 3:30 p.m.  Late Breaking Oral Communications

3:30 – 4:00 p.m.  Oral Communications

4:00 – 4:30 p.m.  Coffee Break and Poster Session

4:30 – 5:00 p.m.  **Keynote 4** - Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

5:00 – 6:00 p.m.  Symposium 4 - Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepidine in Mild-to-Moderate Alzheimer’s Disease

**Saturday, November 4**

8:30 – 10:00 a.m.  Oral Communications

10:00 – 10:30 a.m.  Coffee Break and Poster Session

10:30 – 11:00 a.m.  Late Breaking Oral Communications

11:30 – 12:30 p.m.  Symposium 5 - Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities

12:30 – 1:30 p.m.  Lunch and Poster session

1:30 – 2:15 p.m.  Clinical Trials Prescreening Focus Panel

2:15 – 3:15 p.m.  Oral Communications

3:15 – 4:15 p.m.  Late Breaking Communications

4:15 – 4:30 p.m.  Closing Session
Welcome from the Organizing Committee and Presentation of the CtaD Lifetime Achievement Award to Prof. Bruno Dubois
Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner

Keynote 1
The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
Introduction: Bruno Vellas, MD, PhD, University Hospital of Toulouse, France
Reisa Sperling, MD Harvard Medical School - Center for Alzheimer Research and Treatment Brigham and Women’s Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

Late Breaking Oral communications
Chairs: Rachelle Doody, Philip Scheltens

LB1 - Utilizing a PK/PD model to enable design principles within the gantenerumab Phase 3 Graduate program
Rachelle Doody, MD PhD1, Ronald Gieschke, MD, PhD2, Daniel Serafin, PhD2, Sylvie Retout PhD2, Paul Delmar PhD1, Mirjana Adjeilrovic, PhD, Danielle Abi-Saab, PhD, Smiljana Milosavljevic-Ristic, MD, Paulo Fontura, MD, PhD, Carsten Hofmann, PhD2
(1) Roche Product Development, Neuroscience, Basel, Switzerland (2) Roche Pharma Research and Early Development, Clinical Pharmacology and Bioanalytical R&D, Basel, Switzerland

LB2 - Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden - Results for the Marguerite and Scarlet Road Open Label Extension Studies
Gregory Klein, PhD 1, Paul Delmar PhD 2, Carsten Hofmann, PhD, Mirjana Adjeilrovic, MD, Danielle Abi-Saab, MD2, Smiljana Milosavljevic-Ristic, MD2, Monika Baudier, PhD2, Paulo Fontura MD, PhD2, Rachelle Doody, MD2
(1) Roche Pharma Research and Early Development, Clinical Pharmacology and Bioanalytical R&D, Basel, Switzerland (2) Roche/Cenerrech Product Development, Neuroscience, Basel, Switzerland

LB3 - Efficacy and safety of S 47445, a modulator of AMPA glutamatergic receptors, in patients suffering from Alzheimer’s disease at mild to moderate stage with depressive symptoms.
Pueyo Maria, MD, PhD1, Bernard Katy, PhD, Bretin Sylvie, PharmD, PhD1, Gouttefangeas Sylvie, MD1, Holthoff-Detto Viera, MD2 and Robert Philippe, MD3

LB4 - Phase IIa study results with the glutaminylcyclase inhibitor PQ912 in early Alzheimer’s Disease
Philip Scheltens1, MD, PhD, Mejer Hallihainen1, MD, PhD, Timo Grimmer1, MD, Thomas Duning1, MD, Alida A. Gouw1–6, MD, PhD, Alle Meije Winth1, PhD, Paul Maruff7, BSc (Hons), PhD, G. Caroline M. van Baal8, PhD, Suzanne Bruins3, MSc, Inge Lues3, PhD, Charlotte E. Teunissen1, PhD, Niels D. Prins1, MD, PhD
(1) Alzheimer Centre and Department of Neurology, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands (2) University of Eastern Finland, Institute of Clinical Medicine, Kuopio, Finland (3) Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany (4) Department of Neurology, University of Münster, Münster, Germany (5) Department of Clinical Neurophysiology and MEG Center, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands (6) Department of Radiology, Nuclear Medicine and PET Research, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands (7) Cogstate Ltd, Melbourne, Australia (8) Julius Center for Health Sciences and Primary Care, UMC Utrecht, The Netherlands (9) Julius Clinical, Zelst, The Netherlands (10) Probiodrug AG, Halle, Germany (11) Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands

End of the Scientific Program
6 p.m.
6:15 - 8:00 p.m.

Turning Point Documentary
Please join filmmaker James Keach for a reception with refreshments
In the gripping new documentary “The Turning Point,” acclaimed filmmaker James Keach takes us inside the quest for the first medication that could treat the underlying process of Alzheimer’s disease, more than a century after Dr. Alois Alzheimer first described the brain disorder that slowly destroys memory and cognitive skills. Along the way, we meet the people behind these grand experiments, the scientists driven as much by personal conviction as professional innovation. We discover why medical science is never easy, often unpredictable and potentially perilous – and, as America’s preeminent scientist Neil deGrasse Tyson reminds us, always worth the pursuit. The project was funded through an unrestricted grant by Eli Lilly and Company to Volunteers of America
Thursday, November 2

8:30 – 10:00 a.m.

**Oral Communications**

**Chairs:** Jeffrey Cummings, Kathryn V. Papp

**OCI - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LMI1A-31-BH5** p75 neurotrophin receptor ligand.

Franc M. Longo, MD, PhD1; Manfred Windisch, PhD2; Niels Andreasen, MD3; Agneta Nordberg, MD, PhD4;


**OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly**

Bernard Hanseeuw1, Beth Mormino3, Alex Becker1, Aaron Schultz1, Jorge Sepulcre, Kathryn Papp1, 4, 5, Heidi Jacobs1, Jasmeer Chhatwal1, Dorene Rentz2, 3, Reisa Sperling MD4, and Keith Johnson1, 3, 4;

1. Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; 2. Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; 3. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 4. Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

**OC3 - Clinical evaluation of 18F-PI-2620, a next generation TAO PET agent in subject with Alzheimer disease and progressive supranuclear PALSY**

Andrew Stephens1, John Seibyl2, Andre Mueller1, Olivier Barret2, Mathias Berndt3, Jennifer Madonia4, David Alagille5, Hanno Schieferstein1, Heiko Kroth1, Santiago Bullich4, Andrea Pfeifer3 Andreas Muhs1, Gilles Tamagnan1, Kenneth Marek2, Ludger Dintelborge3;

1. Piramal Imaging, Berlin, Germany; 2. Molecular Neuroimaging, Neu Haven, USA; 3. AC Immune SA, Lausanne, Switzerland.

**OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Processing : The PACC 5**

Kathryn V. Papp PhD1, Dorene M. Rentz PsyD2, 5, Irina Orlovsky MA3, Reisa A. Sperling MD2, Elizabeth C. Mormino PhD3, 4;

1. Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA; 2. Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 3. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, USA.

**OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials? From EHR to Web-Based Cognitive Tests and e-Consent.**

Peter Schueker, MD1, Michael W. Weiner, MD1, J. Wessson Ashford, MD, PhD2, Bruno Vellas, MD, PhD3;

1. UCSF, San Francisco, USA; 2. ICON, Langen, Germany; 3. University Duisburg-Essen, Germany; 4. Stanford/VA Alzheimer’s Disease and Aging Clinical Research Centers, CA, USA; 5. SVA Palo Alto Health Care System, CA, USA; 6. Stanford University, CA, USA;

**OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: a Missing Piece of the Alzheimer’s Puzzle**

Jeffrey Cummings MD1, Sandrine Andrieu MD, MPH2, Philip Scheltens MD, PhD3, Kaj Blennow MD, PhD4, Petr Kocis PhD4, John A. Hey PhD5, A. Power, MD, Martin Tolar, MD, PhD, Susan Abushakra, MD5;

1. Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada; 2. University of Toulouse, Toulouse, France;

**OC7 - ABBV-8E12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study**

Kumar Budur1, Hana Florian, Deli Wang, Weinig Robisc, Molly Soares, Joel B. Braunstein, David M. Holtzman, Randall J. Bateman1, Beatrice Rendenbach-Mueller1, Nuno Mendonca2, 3, 4, 5, 6, 7, 8, 9, 10;

1. AbbVie Inc; North Chicago, IL, USA; 2. C2N Diagnostics LLC; Saint Louis, MO, USA; 3. Washington University, St. Louis, MO, USA; 4. AXA Research Fund & UPMC Chair, Paris, France; 5. Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; 6. AXA Research Fund & UPMC Chair, Paris, France; 7. Katholieke Universiteit Leuven, Leuven, Belgium; 8. Hospital of the University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia; 9. Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; 10. Ledcourt Associates, UK; (10) Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia.

10:00 – 10:30 a.m.

**Coffee Break and Poster Session** (Georgian Room)

10:30 – 11:30 a.m.

**Oral Communications**

**Chairs:** Rebecca E. Amarglio, Pierre-Jean Ousset

**OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring**

Maryam Shoai, PhD1, Richard Pithey, PhD2, Valentina Escott-Price, PhD2, 3, Simon M Laws, PhD2, Harald Hampel, MD, PhD2, Simone Lista, PhD2, Rik Vanderbergh, Isabelle Cleyne, David Irwin, MD, PhD, Greg Davison, PhD, Virginia M.-Y. Lee, PhD, PhD, John Q. Trojanowisky, MD, PhD, John Hardy, PhD, DSc1;

1. UCL Institute of Neurology, London, United Kingdom; 2. Cytos Ltd, UK Oxford, United Kingdom; 3. Cardiff University, Cardiff, United Kingdom; 4. Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; 5. AXA Research Fund & UPMC Chair, Paris, France; 6. Katholieke Universiteit Leuven, Leuven, Belgium; 7. Hospital of the University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia; 8. Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; 9. Ledcourt Associates, UK; 10. Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia.
OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study
Rebecca E. Amariglio PhD1,2,3, Rachel F. Buckley PhD2,4,5, Elizabeth C. Mormino PhD2,3, Dylan R. Kim MPH2, Gad A. Marshall MD2,3, Keith A. Johnson MD1,2,3, Dorene M. Rentz PsyD2,3, Reisa A. Sperling MD1,2,3
(1) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA ; (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (3) Harvard Medical School, Boston, MA, USA ; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia ; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program: Evaluating CNP520 Efficacy in Preclinical Alzheimer’s Disease
Cristina Lopez Lopez, MD, PhD1, Pierre N. Tariot, MD2, Angelita Caputo, PhD1, Fonda Liu, Pharm.D1, Marie-Emmanuelle Riviere, PhD1, Marie-Laure Rouzade-Dominguez, PhD1, Ronald G. Thomas, PhD1, Jessica B. Langbaum, PhD2, Rob Lenz, MD, PhD2, Eric M. Reiman, MD, PhD3, Ana Graf, MD1.
(1) Novartis Pharma, Basel, Switzerland ; (2) Banner Alzheimer’s Institute, Phoenix, AZ; USA ; (3) University of California-San Diego, San Diego, CA, USA.

Symposium 1
CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials
Moderator : Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA
Fabian Model Ph.D.
Roche, Basel Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

Panel discussion
*only for attendees who purchased the lunch package

OC11 - A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer’s Disease.
Adam Boxer, MD, PhD1; Zachary Miller, MD, MD1, Richard Tsai, MD, MBA1, Mary Koestler, RN, Ph.D1, Julio Rojas, MD, Ph.D1, Peter Lubben, MD, MD1, Howie Rosen, MD, MD1, Gil Rabinovici, MD1, Anne Fagan-Niven, Ph.D1, Yann Cobigo, Ph.D1, June Jung, PhD1, Phil Luong, BS1, Emmeline Chuu, BA1, Ryan Powers, BA1, Paige Mumford, BA1, Bruce Miller, MD1, Erik Roberson, MD, PhD1.
(1) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA ; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA ; (3) Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA

OC12 - High dose B Vitamin therapy selectively improves cognitive function indicative of cerebrovascular status in the randomized FAVORIT Ancillary Cognitive Trial
Tammy M. Scott1,2, Aron M. Troen1,3, Irwin H. Rosenberg1,2
(1) Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA ; (2) Friedman School of Nutrition Science and Policy, Tufts University, Boston MA ; (3) Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel

OC13 - Investigational New Alzheimer’s Drug Tricaprilin: Results of a Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease Patients
Samuel Henderson, PhD1, Michael Gold, MD1, Judith Walther, MD1, Sabrina Greer1, Janet Vogel1, Aaron Shenkin1
(1) Accera Inc, Boulder, CO, USA ; (2) PPD Inc, Wilmington, NC, USA

OC14 - Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab’s unique mechanism of action
William J. Meilandt1, Janice A. Maloney1, Jose Imperio1, Travis W. Bainbridge2, Milte Reichelt1, Danielle Mandillian1, Yannepi Lu1, James A. Ernst1, Reina N. Fujii1, Jasvinder K. Atwal1,2
(1) Department of Neuroscience, Genentech, South San Francisco, CA, USA ; (2) Department of Protein Sciences, Genentech, South San Francisco, CA, USA ; (3) Department of Research Pathology, Genentech, South San Francisco, CA, USA ; (4) Department of Preclinical and Translational Pharmacology, Genentech, South San Francisco, CA, USA ; (5) Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA ; (6) Department of Safety Assessment, Genentech, South San Francisco, CA, USA
Keynote 2
From Academy to Industry: Perspectives for Drug Trials in AD
Introduction: Michael Weiner, MD, University of California San Francisco (UCSF) USA
Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland

Late Breaking Oral Communications
Chairs: Virginia Pérez-Grijalba and Chin Hong Tan

LB5 - Targeting Tau with RO7105705: Phase I results and design of a Phase II study in prodromal-to-mild AD
Geoffrey A. Kerchner, MD, PhD; Gai Ayalon, PhD; Mira Blundstrup, MA; Flavia Brunstein, MD, PhD; Priya Chandra, PhD; Akash Datwani, PhD; Reina N. Fuji, VMD, PhD; Paul Manser, PhD; Rajesh Menon, MBA; Sandra Sanabria Bo-horquez, PhD; Edmond Tang, MD, PhD; Michael Ward, PhD; Robby Weimer, PhD; Kristin R. Wildsmith, PhD; Corinne Foo-Akins, MBBS, MBA, MSc
Genentech, Inc., a member of the Roche Group, South San Francisco, CA, USA

LB6 - Plasma Aβ42/40 detects early stages of AD in the AB255 study and correlates with neuroimaging and CSF biomarkers.
Virginia Pérez-Grijalba1, Judith Romero1, Pedro Pesini1, Leticia Sarasa1, Itziar San-José1, Javier Arbizu2, Pablo Martínez-Lage2, Lluís Taragà2, Águstin Ruiz2, Merce Boada2, Manuel Sarasa and The AB255 Araclon Group3
(1)Araclon Biotech S.L., Zaragoza, Spain; (2)Clínica Universitaria de Pamplona, Pamplona, Spain; (3)Fundación CITA-Alzheimer, San Sebastián, Spain. (4)Alzheimer Research Center and Memory Clinic. Fundación ACE. Institut Català de Neurociències Aplicades. Barcelona, Spain

LB7 - Aducanumab 36-month data from prime: A randomized, double-blind, placebo controlled Phase IB study in patients with prodromal or mild Alzheimer’s disease
Samantha Budd Haeberlein, PhD1, Sarah Gheuens, MD, PhD1, Tianle Chen, PhD1, John O’Gorman, PhD1, Philipp von Rosenstiel MD, Ping Chiao, PhD1, Guanfang Wang, PhD1, Christian von Huhn, MD, PhD1, LeAnne Skordos, PharmD, Ping Chiao, PhD1, Guanfang Wang, PhD2, Christian von Hehn, MD, PhD3, LeAnne Skordos, PharmD, Ping Chiao, PhD1, Guanfang Wang, PhD2, Christian von Hehn, MD, PhD3
(1)Biogen, Cambridge, MA, USA (2) Cytel, Cambridge, MA, USA (3) Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LB8 - Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition
Chin Hong Tan, PhD, Chun Chieh Fan, MD, Elizabeth C. Mormino, PhD; Leo P. Sugrue, MD, PhD; Iris J. Broce, PhD; Christopher P. Hess, MD, PhD; William P. Dillon, MD; Lute W. Bonham, BS; Jennifer S. Yokoyama, PhD; Celeste M. Karch, PhD; James B. Brewer, MD, PhD; Gil D. Rabinovici, MD; Bruce L. Miller, MD; Gerard D. Schellenberg, PhD; Karolina Kauppi, PhD; Howard A. Feldman, MD; Dominic Holland, PhD; Linda K. McEvoy, PhD; Bradley T. Hyman, MD, PhD; Ole A. Andreassen, MD, PhD; Anders M. Dale, PhD; and Rahul S. Desikan, MD, PhD for the Alzheimer’s Disease Neuroimaging Initiative
(1) Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA (2) Department of Cognitive Science, UCSD, La Jolla, CA, USA (3) Department of Radiology & NeuroBiological Sciences, Stanford University, Stanford, CA, USA (4) Department of Neurology, UCSF, San Francisco, CA, USA (5) Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA (6) Department of Neurosciences, UCSD, La Jolla, CA, USA (7) Department of Radiology, UCSF, La Jolla, CA, USA (8) Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA (9) Department of Neurology, MGH, Boston, MA, USA (10) NOTIEMENT Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Coffee Break and Poster Session (Georgian Room)

Symposium 2
EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease
Presentation by Michael Egan MD, Merck & Co., Inc., Kenilworth, NJ, USA
Followed by Panel Discussion with
Paul Aisen MD, University of Southern California (USC), San Diego, CA, USA
Maria Carrillo PhD, The Alzheimer Association, Chicago, IL, USA
Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
Bruno Vellas, MD, PhD University Hospital, Toulouse, France
Oral Communications

Chairs: Merce Boada and Bengt Winblad

OC15 - Long-Term Cognitive Decline in Patients with Alzheimer’s Disease in Association with Treatment with Cholinesterase inhibitors-data from SveDem, the Swedish Dementia Registry
Maria Eritsdotter MD, PhD 1,2, Sara García-Ptacek MD, PhD 1,2, Ingemar Käréholt PhD 1,2, Dorota Religa MD, PhD 1,2, Peter Nordström MD, PhD 1, Anders Wimo MD, PhD 1,2, Bengt Winblad MD, PhD 1,2
1 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden; 2 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet and Stockholm University, Stockholm, Sweden; 3 Institute of Gerontology, School of Health and Welfare, Jönköping University, Jönköping, Sweden; 4 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; 5 Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden; 6 Primary Health Care of Hudiksvall-Nordanstig, Sweden

OC16 - Selection of Amyloid Positive Pre-Symptomatic Subjects using Automatic Analysis of Neuropsychological and MRI Data for Cost-Effective inclusion Procedures in Clinical Trials
Maron Ansart, MSc1,2, Stéphane Epelbaum, MD, PhD 1,2,3, Olivier Colliot, PhD 1,2, Didier Dormont, MD 1,2, Bruno Dubois, Prof., MD 1,2, Harald Hampsch, Prof., MD, PhD 1,2,3, Stanley Durrieume, PhD 2, for the ADNI, and the INSIGHT study group
1 Sorbonne Universités, UPMC Univ Paris 6, Inserm, CNRS, Institut du cerveau et de la moelle (ICM) - Hôpital de la Pitié-Salpêtrière, Boulevard de l’Hôpital, Paris, France; 2 Inria, Paris, France; 3 Department of Neurology, Insitut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Boulevards de l’Hôpital, Paris, France; 4 AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, Insitut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Paris, France; 5 AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurobiology, Paris, France; (6) AXA Research Fund & UPMC Chair, Paris, France

OC17 - Physical Activity and Longitudinal Cognition: Results from the Harvard Aging Brain Study
Hannah M. Klein1, Dylan R. Kirn, MPH1, Aaron P. Schultz, PhD 1, Jennifer S. Rabin, PhD 1, Rachel Buchley, PhD 1,2, Doreene M. Rents, PsyD 1,2, Kathyn V. Papp, PhD 1,2, Keith A. Johnson, MD 1,2, Reisa A. Sperling, MD, MMSc 1,2, Jasmeer P. Chhatwal, MD, PhD 1,2,3,4,5,6
(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (2) Department of Radiology, Brigham and Women’s Hospital, Boston, MA, USA; (3) Harvard Medical School, Boston, MA, USA; (4) Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; (5) Florey Institutes of Neurosciences and Mental Health, Melbourne, Australia; (6) Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia

OC18 - Validation of Tau PET Imaging in Alzheimer’s Disease and Other Tauopathies
Nítilias Mattsson, MD, PhD 1,2, Michael Schöll MD, PhD 1, Tomas Ohlsson MD, PhD 1, Andreas Hahn MD, PhD 1, Olof Strandberg MD, PhD 1, Jonas Jögi MD, PhD 1, Ruben Smith MD, PhD 1, Oskar Hansson MD, PhD 1,2
(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden; (2) Memory Clinic, Stöne University Hospital, Malmö, Sweden; (3) Department of Radiation Physics, Stöne University Hospital, Lund, Sweden; (4) Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; (5) Department of Clinical Physiology and Nuclear Medicine, Stöne University Hospital, Lund, Sweden; (6) Department of Neurology, Stöne University Hospital, Lund, Sweden

OC19 - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update
Kathleen A. Welsh-Bohmer, PhD 1, Brenda L. Plassman, PhD 1, Carl Chiang, PhD 1, Meredith Culp, BS 1, Patrick Harrigan, BChE 1, Janet O’Neill, MBA 1, Ryan Walter, BS 1, Stephen Haneline, MS 1, Julian Arbuckle, BSc (Hons) 1, Shyama Brewster, BSc (Hons) 1, Yuka Maruyama, D.V.M. 1, Tom Swanson, BSCE, MBA 1, Dominic Fitzsimmons, BSc (Hons) 1, Alexandra S. Atkins, PhD 1, Sarah Powell, MSN 1, Richard Keefe, PhD 1, Craig Metz, PhD 1, Deborah Yarbrough, MS, MBA 1, Daniel K. Burns, PhD 1, Ann M. Saunders, PhD 1, Robert Alexander, MD 1 for the TOMMORROW study investigators
(1) Department of Psychiatry & Neurology, Duke University, Durham NC, USA; (2) Zinfandel Pharmaceuticals, Inc., Chapel Hill NC, USA; (3) Takeda Development Center Americas, Inc, Deerfield, IL, USA; (4) NeuroCog Trials, Durham, NC, USA

OC20 - Emerging Plasma-Based Therapies for AD
Montserrat Costa PhD 1, Raquel Horillo PhD 1, Ana M Ortiz MSc 1, Alba Pérez PhD 1, Laura Núñez BSc 2, Antonio Páez MD 1, Mercè Boada MD 1, Agustín Ruiz MD, PhD 1, Salvador Grancha PhD 1
(1) Research & Development, Grifols Bioscience Industrial Group, Pares de los Valles, Spain; (2) Clinical Operations Department, Grifols Bioscience Industrial Group, Sant Cugat del Vallés, Spain; (3) Memory Clinic of Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain

Coffee Break and Poster Session (Georgian Room)

10:00 – 10:30 a.m.

Keynote 3
Genetic Aspects In Clinical Trials
Introduction: Randall Bateman, MD - Washington University School of Medicine, St Louis, MO - USA
John Hardy, PhD - Reta Lila Weston Institute of Neurological Studies, University College London, London UK
12:30 – 1:30 p.m. Lunch* (ABC Rooms)  *only for attendees who purchased the lunch package and Poster Session (Georgian Room and Ballroom Foyer)

1:30 – 2:30 p.m. Symposium 3

Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin

Moderator: Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. Role of 5-HT2A Receptors in the Pharmacology of Alzheimer’s disease Psychosis

Stephen M. Stahl, MD, PhD, Ethan S. Burstein, PhD

(1) University of California, San Diego, CA, USA; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis

Clive Ballard, MBChB, MRCPsych, Carol Banister, MBChB, MRCPsych, Jim Youakim, MD, Bruce Coate, MPH, Srdjan Stanitkovic, MD, MSPH, on behalf of the ADP Investigators

(1) University of Exeter Medical School, Exeter, UK; (2) King’s College, London, UK; (3) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials

Pierre N. Tariot, MD, Randall Owen, MD, Doral Fredericks, PharmD, MBA

(1) Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA
Late Breaking Oral Communications

Chairs: Peter J. Snyder and Christopher van Dyck

**LB9 - Amylin type peptides as a new therapeutic avenue for Alzheimer's disease**

Wendy Qiu, M.D., Ph.D.,1,2 Haihao Zhu, M.D., Ph.D.,3 Robert A. Stern, Ph.D.,4 Qishuan Tao, Ph.D.,3 Gustavo A. Mercier, M.D., Ph.D.,5 Martin Farlow, M.D., Ph.D.,6 Neil Kowall, M.D., Ph.D.1

(1) Alzheimer's Disease Center, (2) Department of Psychiatry, Boston University School of Medicine, Boston, MA, (3) Department of Pharmacology, Boston University School of Medicine (4) Department of Radiology, Boston University School of Medicine, Boston, MA, USA (5) Alzheimer's Disease Center, Indiana University, Indianapolis, IN, USA

**LB10 - Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer’s Disease: A New Biomarker for Clinical Trials?**

Ming-Kai Chen, MD, PhD1, Adam P. Mecca, MD, PhD 2, Mika Naganawa, PhD1, Sjoerd J. Finnema, PhD1, Takuya Toyonaga, PhD,1, Shu-fei Liu, PhD1, Julia W. McDonald1, Hannah R. Michaela1, Nabeel M. Nabulsi, PhD1, Yi Yun Huang, PhD1, Amy F. T. Arnsen, PhD3, Richard E. Carson1,4, and Christopher H. van Dyck2,3,5

(1) Department of Radiology and Biomedical Imaging, Yale Positron Emission Tomography Center, Yale University, New Haven, CT, USA; (2) Department of Psychiatry, Yale University, New Haven, CT, USA; (3) Department of Neuroscience, Yale University, New Haven, CT, USA; (4) Department of Biomedical Engineering, Yale University, New Haven, CT, USA; (5) Department of Neurology, Yale University, New Haven, CT, USA

**LB11 - Early change in Retinal Structural Anatomy during the preclinical stage of Alzheimer’s disease**

Peter J. Snyder, PhD1, Cláudia Y. Santos, MS2, Jessica Alber, PhD1, Lenworth N. Johnson, MD3, Stuart Sinoff, MD3; Stuart Sinoff, MD4, & Paul Maruff, PhD5,6

(1) Department of Neurology, Rhode Island Hospital & Alpert Medical School of Brown University, Providence, RI, USA (2) Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA (3) Department of Ophthalmology, Rhode Island Hospital & Alpert Medical School of Brown University, Providence, RI, USA (4) Department of Neurology, BayCare Medical Group, Clearwater, FL, USA (5) Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (6) Cogstate Ltd, Melbourne, Victoria, Australia

**LB12 - Online study partner-reported subjective cognitive decline can help identify potential Alzheimer’s clinical trial participants**

Nosheny RL,1,3 Camacho M1, Insel PS1,3, Machin RS PhD2, Finley S MS1, Fenniken D1, Foehrer J1, Truran-Sacrey D1, Maruff P4, and Weiner MW,1,3

(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA (2) UCSF Department of Psychiatry, San Francisco, CA (3) UCSF Department of Radiology and Biomedical

**Oral Communications**

Chairs: Régis Bordet and Craig Ritchie

**OC27 - The European Prevention of Alzheimer’s Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer’s Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.**

Andrew Satlin, MD1, Craig Ritchie MD PhD2, Miia Kivipelto MD PhD2, Alina Soloman MD PhD3, Brian Tom PhD4, Jose Luis Molinuevo MD PhD5, Scott Berry PhD6, Frederik Barboh MD PhD7, Gill Farrar PhD8

(1) Eisai Pharmaceuticals, USA (2) Centre for Dementia Prevention, University of Edinburgh, UK (3) Ageing Research Centre, Karolinska Institute, Sweden (4) MRC Biostatistics Unit, University of Cambridge, UK (5) Barcelona Beta Brain Research Centre, Spain (6) Berry Consultants Ltd, Texas, USA (7) VU University Medical Centre, Amsterdam, The Netherlands (8) General Electric, Amersham, UK

**OC28 - Towards a New Biomarker Battery for Drug Development in Alzheimer’s Disease**

Olivier Blin, MD, PhD1, Régis Bordet MD PhD2, Jill Richardson PhD1, Pierre Payoux MD PhD3, Claudio Babiloni MD PhD3, David Bartrès-Faz MD PhD3, Catherine Cassé-Perot PhD1 Giovanni Frisoni MD PhD7

(1) University of Aix-Marseille (2) University of Lille (3) CSK (4) University of Toulouse (5) University of Roma (6) University of Barcelona (7) University of Geneva

**Coffee Break and Poster Session** (Georgian Room and Ballroom Foyer)

**Keynote 4**

Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

Introduction: Howard Feldman, MD, University of California at San Diego (UCSD) - USA

Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ - USA

**Symposium 4**

Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepirdine in Mild-to-Moderate Alzheimer’s Disease
Oral Communications

Chairs: Audrey Gabelle, Zaven Khachaturian

OC29 - Ory-2001 Rationale in Mild to Moderate Alzheimer’s Disease

Roger Bullock MD, Cesar Molinero MD, PhD, Tamara Maes PhD
(1) Oryzon Genomics S.A, Barcelona, Spain

OC30 - Plasma Amyloid Levels within the Alzheimer’s Process and Correlations with Central Biomarkers

Olivier Hanon, MD, PhD, Jean-Sébastien Vidal, MD, PhD, Sylvain Lehmann, MD, PhD, Sébastien Bombois, MD, PhD, Bernadette Allinquant, MD, Marie Godard, MD, Patrick Gelé, MD, Christine Delmearé, MD, Frédéric Blanch, MD, PhD, S. Schraen, MD, Audrey Gabelle, MD, PhD and the BALTAZAR study group.
(1) Department of Gerontology, Broca Hospital, Paris, France; (2) Laboratoire de Protéomique Clinique, Department of Biochemistry, Saint-Eloi Hospital, Rennes, Inserm U1183, France; (3) CNRPS de Lille, Department of Neurology, Lille, France; (4) Centre de Psychiatrie et Neurosciences, Université Paris Descartes, Paris, France; (5) University of Lille Nord de France, Department of Biology and Pathology, Lille University Hospital, INSERM U972, 59037 Lille, France; (6) CMRPS de Strasbourg, Department of Gerontology, Strasbourg, France; (7) CMRPS de Montpellier, Department of Neurology, Inserm U1183, Montpellier, France.

OC31 - Online Clinical Research: Updates and Insights from the Brain Health Registry

Shannon Finley, MA, Diana Truran, Derek Fleniken, Juliet Fochtler, Rachel L. Nosheny, PhD, Monica Camacho, R Scott Machin, PhD and Michael W. Weiner, MD
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Administration Medical Center, San Francisco, CA, USA; (2) UCSF Department of Psychiatry, San Francisco, CA, USA; (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA.

OC32 - BPN14770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer’s Dementia: Preclinical, PET Imaging and Human Phase I Results

Mark Gurney PhD, Chong Zhang PhD, Ying Xu PhD, James O’Donnell PhD, Masahiro Fujita MD, PhD, Robert Innis MD, PhD, Victor Pile PhD, Sanjay Telu PhD and Scott Reines, MD, PhD
(1) Tetra Discovery Partners, Inc. Grand Rapids, MI, USA; (2) School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, USA; (3) National Institute of Mental Health, Bethesda, MD, USA.

OC33 - Amyloid Beta Stable Isotope Labeling Kinetics and Concentrations of Human Plasma Detect CNS Amyloidosis

Vitaliy Ovod MS, Kara Ramsey, BS, James Bollinger PhD, Kwasi Mawuenevega, PhD, Terry Hicks, BA, Theresa Schneider, Thomas Kasten, PhD, Wendy Sigurdson, RN, Melissa Sullivan, MS, Tamara Donahue, RN, Katrina Paumier, PhD, David Holtzman, MD, John Morris, MD, Tammie Benzinger, MD, PhD, Anne Fagan PhD, Bruce Patterson, PhD, and Randall Baleman, MD
(1) Department of Neurology, Washington University School of Medicine, St. Louis, MO; (2) Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO; (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO; (5) Department of Medicine, Washington University School of Medicine, St. Louis, MO.

OC34 - Stereotypical Data-Driven Imaging Biomarker Trajectories across the Alzheimer’s Disease Spectrum

Sergey Shcherbinin, PhD, Mark A. Mintun, MD, Adam J. Schwarz, PhD, For the Alzheimer’s Disease Neuroimaging Initiative
(1) Eli Lilly and Company, Indianapolis, IN, USA; (2) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA; (3) Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)

Coffee Break and Poster Session (Georgian Room and Ballroom Foyer)

Late Breaking Oral Communications

Chairs: Michael Grundman and Philipp von Rosenstiel

LB13 - The Anti-Aβ Oligomer Drug CT1B12 for Alzheimer’s: Phase Ib/2a Safety Trial Outcomes

Lon S. Schneider, MD, Michael Grundman, MD, MPH, MS, Steven DeKoshy, MD, Roger Morgan, MD, Robert Guttendorf, Michelle Higgin, PhD, Julie Pribly, Kelsie Mozonoi, Nicholas J. Izzo, PhD, Hank Safferstein, PhD, Celine Houser, RN, Michael Woodward, MD, Susan M. Catalano, PhD
(1) Keck School of Medicine of USC, Los Angeles, CA, USA; (2) Global R&D, Partners, LLC, San Diego, CA, USA; (3) Cognition Therapeutics, Inc., Pittsburgh, PA, USA; (4) McKnight Brain Institute, University of Florida, Gainesville, FL, USA; (5) MedSurge, LLC, Raleigh, NC, USA; (6) Aclairo Pharmaceutical Development Group, Inc., Vienna, VA, USA; (7) Pharmacies, Cary, NC, USA; (8) Memory and Wound Clinics, Austin Health, Melbourne, Australia.

LB 14 - “Proxy Antigens”: A new, definitive tool to guide successful clinical trials

Reddy Moela, PhD, Ronald N. Zuchermann, PhD, William Shelande, MSE
(1) Arven Alzdet Inc, Bertrily, California, USA; (2) Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
**LB15** - Value of 18F-florbetaben amyloid PET in the diagnostic work-up of most complex patients with dementia in France: a naturalistic study

Mathieu Ceccaldi, MD, PhD1; Thérèse Jonveaux, MD2; Antoine Verger, MD, PhD3; Pierre Krolak-Salmon, MD, PhD4; Claire Houzard, MD5; Olivier Godefroy, MD6; Trevor Shields, MD7; Audrey Perrotin, PhD8; Rossella Gismondi, MD9; Santiago Bullich, PhD10; Aleksandar Jovaletic, PhD11; Nicola Raffa, MSIO12; Florence Pasquier, MD13; Franci Sernah, MD14; Bruno Dubois, MD15; Marie Odile Habert, MD16; David Wallon, MD17; Mathieu Chastan, MD18; Pierre Payoux, MD19; Andrew Stephens, MD, PhD20; Eric Guedj, MD, PhD21.

(1) AP-HM - Hôpital de la Timone, Neurology and Neuropsychology Department, and Aix Marseille University, Inserm, INS, Institute of Neurosciences des Systèmes, Marseille, France; (2) CHRU de Nancy – Hôpital Brabois, Centricat, Department, Vandoeuvre-les-Nancy, France; (3) INSERM U947, AD, Nancy, France; (4) Clinical and Research Memory Center of Lyon, Hospices civils de Lyon, UCBL, Inserm 1028, Lyon, France; (5) CHU, Lyon, Nuclear Medicine Department, Lyon, France; (6) CHU Amiens Picardie – Hôpital Sud, Neurology Department, Amiens, France; (7) CHU Amiens Picardie – Hôpital Sud, Nuclear Medicine Department, Amiens, France; (8) Piramal Imaging, Medical Affairs, Berlin, Germany; (9) Piramal Imaging, Clinical Research and Development, Berlin, Germany; (10) Piramal Imaging, Market Access and HEOR, Berlin, Germany; (11) Inserm U117, Université de Lille, CHU DistAlz, Lille, France; (12) Univ. Lille, U117, CHU Lille, Nuclear Medicine Department, Lille, France; (13) AP-HP - Hôpital Pitié Salpêtrière, Memory and Alzheimer Disease Institute INCA, Paris, France; (14) Laboratoire d’Imagerie Biomédicale, Sorbonne Universités, UPMC, Univ Paris Inserm U 1146, CNRS UMR 7371, Paris, France; (15) CHU de Rouen - Hôpital Charles Nicolle, Neurology Department, Rouen, France; (16) Centre Henri Beaufays, Nuclear Medicine Department, Rouen, France; (17) Inserm, Toulouse Neuroimaging Center, Université de Toulouse, Inserm, UPS, France; (18) AP-HM – Hôpital de la Timone, Nuclear Medicine Department, and Aix-Marseille University, CERMED, CNRIS, INT, Institut of Neurosciences de la Timone, Marseille, France.

**LB16** - ADUCANUMAB titration dosing regimen: 24-month analysis from prime, a randomized, double-blind, placebo-controlled Phase IB study in patients with prodromal or Mild Alzheimer’s disease

Philipp von Rosenstiel MD1, Sarah Gheuens, MD, PhD 1, Tianle Chen, PhD2, John O’Gorman, PhD3, Ping Chiao, PhD4, Guanfang Wang, PhD5, Christian von Hehn, MD, PhD6, LeAnne Skordos PharmD7, Christoph Hock, MD8, Roger M Nitsch, MD9, Samantha Budd Haeberlein, PhD9, Alfred Sandrock, MD, PhD9.

(1)Biogen, Cambridge, MA, USA (2)Cytel, Cambridge, MA, USA (3)Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

---

**Symposium 5**

**Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities**

**Moderator: Arjen Brussaard, PhD, Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands**

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration

Giovanna Mallucci, MD PhD1,2

(1) Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK ; (2) UK Dementia Research Institute at University of Cambridge, Cambridge, UK

2. Modulation of synaptic and network activity and endocytosis with light flicker therapy reduces amyloid pathology in mouse model of AD

Li-Hueh Tsai, PhD1

(1) Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge MA, USA

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction

John Alam, MD1

(1) EIP Pharma, LLC, Cambridge MA, USA

---

**Lunch** *(ABC Rooms)* *only for attendees who purchased the lunch package and Poster Session* *(Georgian Room and Ballroom Foyer)*
Clinical Trials Prescreening Focus Panel:
Prescreening Initiatives to Identify Individuals with Preclinical or Early Alzheimer’s Disease for Clinical Trials

Moderator: Jamie A Mullen, MD, AstraZeneca, Waltham MA, USA

1. The Funnel study: Prescreening for MCI and mild AD patients from the CHARIOT Register
Geraint J Price, Maxwell J Benjamin, Lisa K Curry, Sabrina Wl Smith and Lefros T Middleton
Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, UK

2. A prescreening study using amyloid PET to improve recruitment for early Alzheimer’s disease drug trials
Christopher C Rowe, MD Austin Health, Melbourne, Australia

3. Models of Patient Engagement in Alzheimer’s Disease (MOPEAD): a European project to move Alzheimer’s disease environment towards an earlier diagnosis
Mercè Boada, MD, PhD1; Laura Campo2; Dhaval Desai3; Hans Peter Hundemer4; Octavio Rodriguez-Gomez, MD; Bengt Winblad, Prof, MD, PhD; Franke Jessen, MD, PhD; Peter Jelle Visser, MD, PhD; Milica Kramberger, MD, PhD; Rafael Simó, MD, PhD; Rafael Navajo5; Annette Dumas5; Jean Georges, BA6; David Krivec5; Peggy Maguire5; Derek MacKenzie5
(1) Fundació ACE. Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; (2) Eli Lilly and Company Ltd, Basingstoke, United Kingdom; (3) AstraZeneca AB, Sodertalje, Sweden; (4) Lilly Deutschland GmbH, Bad Homburg, Germany; (5) Karolinska Institutet, Center for Alzheimer Research, Div. of Neurogeriatrics, Huddinge, Sweden; (6) German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany; (7) Stichting VUMC, Amsterdam, Netherlands; (8) University Medical Center Ljubljana, Ljubljana, Slovenia; (9) Institut de Recerca Hospital Universitari Vall d’Hebron (VHIB), Barcelona, Spain; (10) CMV Soluciones Globales Internet S.A.U., Barcelona, Spain; (11) ASDM Consulting, Auderghem, Belgium; (12) Alzheimer Europe, Luxembourg, Luxembourg; (13) Spominica – Alzheimer Slovenia, Ljubljana, Slovenia; (14) European Institute of Women’s Health, Dublin, Ireland; (15) KITE Innovation (Europe) Ltd, Huddersfield, United Kingdom

Oral Communications

Chairs: Matthieu Ceccaldi and Curtis Tatsuoka

Jason Hassenstab, PhD1,2,3,4, Andrew J. Aschenbrenner, PhD1,2,3,4, Eric McDade, DO1,3,4, Yen Ying Lim, PhD4, Paul Maruff, PhD1,3,4, David A. Balota, PhD1,2,4, John C. Morris, MD1,4, Randall J. Bateman, MD1,3,4, & The Dominantly Inherited Alzheimer Network-Trials Unit.
(1) Department of Neurology, Washington University School of Medicine, St. Louis, MO USA; (2) Department of Psychological & Brian Sciences, Washington University in St Louis, St Louis, MO USA; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), Washington University School of Medicine, St Louis, MO USA; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St Louis, MO USA; (5) Department of Human Development and Family Studies, Pennsylvanina State University, State College, PA USA; (6) The Florey Institute, The University of Melbourne, Parville, Victoria, Australia; (7) Cogstate Ltd, Melbourne, Victoria, Australia

OC36 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloid
Sarah J Carr PhD1, Judith Jaeger PhD2, Nancy Maserejian ScD3, Ahmed Enayatallah4, Alan Lerner5, Yanming Wang6, Sheng Yang7, Wenting Wang7, Shijia Biang5, Curtis Tatsuoka PhD1,5 and for the Alzheimer’s Disease Neuroimaging Initiative*
(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) CogniantMetics, DE USA; (3) Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA; (4) Biogen, Cambridge, MA, USA; (5) Neurological Institute, University Hospitals Case Medical Center, Beachcoud, OH, USA; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH, USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

OC37 - Alzheimer’s Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from GERAS
Catherine Reed, PhD1, Mark Belger, BSc1, J. Scott Andrews, PharmD2, Anjte Tochhorn-Heidenreich, MSc1.
(1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly and Company, Indianapolis, IN, USA

OC38 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25-35 Peptide-Induced Toxicity in Mice.
Guillaume J. Blivet, MS1, Johann Meunier, PhD2, Francois J. Roman, PhD2, Jacques Touchon, MD, PhD3,4
(1) REGENT-IJeF SAS, Montpellier, France; (2) Amylegen SAS, Montferrier-sur-Lez, France; (3) INSERM U1061, Montpellier, France; (4) University of Montpellier, France
Late Breaking Oral Communications

Chairs: Asa Hatami and Sharon Sha

**LB17** - Differential inhibition of the α-secretase ADAM10 by Aβ40 variants containing FAD mutations
Asa Hatami1, Subrata Dutta2, Alejandro Rodriguez2, Patricia Spilman1, Jevgenij Rastatov2, Charles Glabe1, and Varghese John1
(1) Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (2) Department of Chemistry and Biochemistry, University of California, Santa Cruz

**LB18** - Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease
Mohammad Afshar, MD, PhD1; Frédéric Parmentier, PhD2; Ene I Ette, PhD2; Emmanuel O Fadiran, PhD3; Christopher U Missling, PhD3; (1) Ariana Pharma, Paris, France, (2) Anoixis Corp., Natick, MA, (3) Anavex Life Sciences Corp., New York, NY

**LB19** - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
Sharon J. Sha, MD, MS1; Gayle K. Deutsch, PhD2; Lu Tian, ScD, MS2; Kara Richardson3; Maria Coburn3; Jennifer Gaudioso4; Ethan Solomon, MS5; Athanasia Boumis4; Anthony Bet2; Steven P. Braithwaite, PhD6; Sam Jackson, MD, MBA1; Karoly Nikolich, PhD1; Tony Wyss-Coray, PhD1; (1) Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA (2) Department of Health Research and Policy, Stanford University, Stanford, CA, USA (3) Department of Neurosurgery, Stanford University, Stanford, CA, USA (4) Department of Pediatrics, Stanford University, Stanford, CA, USA (5) Endocrinology, University of Southern California, Los Angeles, CA, USA (6) Alkahest, San Carlos CA, USA

**LB20** - Application of the revised diagnostic criteria for the early stages of Alzheimer’s disease to the LipiDiDiet study population
Tobias Hartmann, PhD1,2; Kaj Blennow, PhD3,4; Pieter Jelle Visser, PhD5; Milla Kiwipelo, MD, PhD6; Hilttta Soininen, MD, PhD1,2,3; Suzanne B Hendrix, PhD10, on behalf of the LipiDiDiet clinical study group (1) Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany (2) Department of Experimental Neurology, Saarland University, Homburg, Germany (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden (4) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden (5) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands (6) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands (7) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland (8) Department of Clinical Geriatrics, NIVS, Karolinska Institutet, Huddinge, Sweden (9) Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden (10) Pentara Corporation, Salt Lake City, UT, USA (11) Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland

Closing Session
### Wednesday, November 1 and Thursday, November 2:
All posters presentations will be in Georgian Room (Mezzanine Level)

- **Theme 1. Clinical trials: Methodology**
  Pages 20 - 23
  
  P1 to P25 and LBPI1 to LBPI2

- **Theme 2. Clinical trials: Results**
  Pages 24 - 26
  
  P26 to P42 and LBPI25 to LBPI32

- **Theme 11. New therapies and clinical trials**
  Pages 27 - 29
  
  P114 to P129 and LBPI15 to LBPI24

### Friday, November 3 and Saturday, November 4:
All posters presentations will be in Georgian Room and Ballroom Foyer (Mezzanine Level)

- **Theme 3. Clinical trials: Imaging**
  Pages 30 - 31
  
  P43 to P55 and LBPI35 to LBPI38

- **Theme 4. Clinical trials: Biomarkers including plasma**
  Pages 32 - 35
  
  P56 to P77 and LBPI39 to LBPI46

- **Theme 5. Clinical trials: Cognitive and functional endpoints**
  Pages 36 - 37
  
  P78 to P86 and LBPI47 to LBPI49

- **Theme 6. Cognitive assessment and clinical trials**
  Pages 37 - 38
  
  P87 to P92 and LBPI50 to LBPI59

- **Theme 7. Behavioral disorders and clinical trials**
  Page 39
  
  P93 to P96 and LBPI60 to LBPI62

- **Theme 8. Health economics and clinical trials**
  Page 40
  
  P97 to P99 and LBPI63 to LBPI64

- **Theme 9. Epidemiology and clinical trials**
  Pages 40 - 41
  
  P100 to P108

- **Theme 10. Clinical Trials: Animal Models**
  Page 42
  
  P109 to P113 and LBPI13 to LBPI14
Wednesday, November 1 and Thursday, November 2

Theme 1. Clinical trials : Methodology

P1: Japanese ADNI: Clinical, neuroimaging and biomarker profiles in comparison with ADNI
Takeshi Iwatsubo, MD,1 Atsushi Iwata, MD,1 Kazushi Suzuki, MD,1 Ryoko Ihara, MD,1 Hiroyuki Arai, MD,1 Kenji Ishii, MD,1 Michio Senda, MD,1 Kengo Ito, MD,1 Takeshi Iiheuchi, MD,1 Ryozo Kuwano, MD,1 Hiroshi Matsuda, MD,1 for the Japanese ADNI and Chung-Kai Sun, PhD, Laurel Beckert PhD,1 Paul Aisen, MD8, Michael Donohue, PhD,9 for the ADNI

P2: Putting the PGSA to the test: Time to progression in five studies with MCI patients
Manfred Berres, PhD, RheinAhrCampus, Remagen, Germany; Andreas U. Monsch, PhD, Memory Clinic, University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland and René Spiegel, PhD, University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland.

P3: The importance of correct specification of the within-subject correlation structure in sample size calculation and power analysis for an AD clinical trial utilizing mixed effects regression analysis for outcome assessment
Wenyaw Chan, Ph.D1, Ho-Lan Peng, Ph.D1, Valory N. Pavlik, Ph.D.2

P4: Join Dementia Research Improving Delivery of Clinical Trials in the UK
Adam Smith, Office of the NIHR National Director for Dementia Research, University College London, UK

P5: Evaluation of Rapid, on-Site APOE Genetic Testing for Subject Outreach and Trial Recruitment
Sharon Cohen, MD FRCPC1, Stephen G. Thein, PhD2, Ian Cohen, MD CCFP1, Sophia Marie Pagtakhan, MD1, Fadi Frankul, MBChB1

P6: Implementing a Memory Clinic Model to facilitate recruitment into early phase clinical trials for Mild Cognitive Impairment and Alzheimer’s Disease
Lovingly Park, Ph.D1, Lev Gertsik, MD2, Zanya Mendoza, PsyD,2, Katrina Patrick, Ph.D.2, Darlene Gullabai, Airybel Rodriguez1, and Stanford Jhee, PharmD1

P7: AD clinical trial recruitment Capacity to screen delivers faster recruitment
Roger Bullock, MD1 Mette G. Shahsen 2 Susanne B. Olesen 3 Aina S. Lihn, MD, PhD 2

P8: Clinical and psychometric characteristics of participants with preclinical Alzheimer’s disease in Japanese ADNI
Ryoko Ihara, MD,1 Atsushi Iwata, MD,1 Kazushi Suzuki, MD,1 Takeshi Iwatsubo, MD1 Hiroyuki Arai, MD,1 Kenji Ishii, MD,1 Michio Senda, MD,1 Kengo Ito, MD,1 Takeshi Iiheuchi, MD,1 Ryozo Kuwano, MD,1 Hiroshi Matsuda, MD,1 for the Japanese ADNI

P9: A novel mixed effects model to simultaneously estimate how the baseline value and the longitudinal change in biomarkers predict the change in cognition in dominantly inherited Alzheimer’s disease
Guoqiao Wang, PhD,1 Chengjie Xiong, PhD, Eric M. McCade, DO1 Jason Hassensnab, PhD1, Anne M. Fagan, PhD1, Tammie L.S. Benzing, PhD,1 John C. Morris, MD1, Andrew J. Aschenbrenner, PhD,1 Randall J. Bateman, MD1

The Dominantly Inherited Alzheimer Network, Department of Neurology, Washington University School of Medicine, St. Louis, MO
P10: An examination of rate of decline as an alternative to change from baseline
Howard Mackey, PhD1, Nan Hu, PhD1, Michael Malek-Ahmadi, MSc2, Yinghua Chen, MSc2, Pierre Tariot, MD2, Eric M Reiman, MD2, Francisco Lopera, MD1, Kewei Chen, PhD2, Ronald Thomas, PhD2
(1) Genentech, Inc., South San Francisco, CA, USA. (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA. (3) Universidad de Antioquia, Medellin, Colombia. (4) UC San Diego Department of Neurosciences, CA, USA

P11: Metric Collection for Research Site Optimization: Global Alzheimer’s platform efforts toward creating an AD research site database.
Richard Mohs, PhD1, Kate Zhong, MD1, John Dwyer, JD1, Jason Borh, MA1, Gabe Goldfeder, MA1
Global Alzheimer’s Platform, Washington, D.C., USA

P12: In vitro degradation of β-amyloid fibrils by microbial keratinases
Debananda Singh Ningthoujam, DBT-State Biotech Hub (SBT Hub) & Microbial Biotechnology Research Laboratory (MBRL), Manipur University, Canchipur, Imphal, India

P13: A likelihood-based prediction of Alzheimer’s dementia using biomarkers: applications for clinical trials
Igor Yakushev, MD1, Felix Müller-Sarnowshi, MD1, Bing Si, PhD1, Jing Li, PhD1, Timo Grimmer, MD1
(1) Dept. of Nuclear Medicine, Technical University of Munich. (2) Dept. of Psychiatry and Psychotherapy, Technical University of Munich. (3) Dept. of Industrial Engineering, Arizona State University

P14: A randomized placebo-controlled cross-over trial investigating nabilone as a treatment for agitation in patients with advanced AD: study protocol
Myuri Ruthriahuban, PhD(e)1,2,3, Nathan Hermann, MD, FRCPC1,2,3, Eileen H. Abraham, BSc1,2,3, Chelsea Sherman, BSc1,2,3, Nicolaas Paul L.G. Verhoeff, MD, FRCP(C)1,2,3, Alex Kos, PhD1, Sandra E. Black, MD, FRCPC1,2, Ana C. Andreazza, PhD1 and Krista L. Lanctot, PhD1,2,3
(1) Sunnybrook Research Institute, Toronto, ON, Canada. (2) University of Toronto, Toronto, ON, Canada. (3) Neuropsychopharmacology Research Group, Toronto, ON, Canada. (4) Baycrest Health Sciences, Toronto, ON, Canada

P15: Enriching Clinical Trial Data through Co-enrollment with the Brain Health Registry
Juliet Fockler1,2, Rachel L. Nosheny PhD1,2, Diana Truran, Shannon Finley, MA1, Monica Camacho1, Derek Flenkoten1, Aaron Ulbricht1, R Scott Machin PhD1,2, Gil Rabinovici MD1,2, and Michael W Weiner MD1,2
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA. (2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA. (3) UCSF Department of Psychiatry, San Francisco, CA, USA. (4) UCSF Department of Neurology, San Francisco, CA, USA

P16: Outcomes and Length of Pharmacotherapy Trials on Alzheimer’s disease
Enea Traini, PhD1, Michele Moruzzi, PhD1, Francesco Amenta, MD1
Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino

P17: Electrophysiology of the GABA and Cholinergic systems in healthy elderly subjects
Kristinn Johnsen, PhD1, Peter Draxler, PhD1, Gisli Johannesson, PhD1, Magnus Johannsson, MSc1, Thorhild Gudmundsson, MD1, Jon Snaedal, MD2
(1) Research and Development, MentiScura, Reykjavík, Iceland. (2) Geriatrics, Landspitali University Hospital, Reykjavík, Iceland.

Christopher Weber, PhD1, Selam Negash, PhD1, Michael Ropachi, PhD1, Christopher Randolph, PhD1
(1) MedAvante, Inc. (2) Loyola University Medical Center

P19: Study design and protocol of the Nolan trial: A randomized controlled trial of a nutritional blend to prevent cognitive decline in older adults
Claudie Hooper, PhD1, Sophie Guyonnet, PhD1,2, Corina Boschat PhD1, Julie Hudry PhD1, Sandrine Andrieu MD, PhD2,3, Jeronen Schmitt PhD1, Bruno Vellas MD, PhD1
(1) Gerontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France. (2) UM1R027, Université de Toulouse, UPS, INSERM, Toulouse, France. (3) Nestlé Research Center, Vers-chez-les-Blanc, Switzerland. (4) Department of Epidemiology and Public Health, CHU Toulouse, Toulouse, France. (5) Center of Human Psychopharmacology, Swinburne University of Technology, Melbourne, Australia.
P20: Validating Trial Power in Presence of Non-Random Dropouts Using Disease Simulation  
Ali Tafazzoli, PhD1, Peter L. Quon, MPH1, Sean Stern, MS1, Anuraag Kansal, PhD1

P21: Accounting for baseline prognostic variables and patient drop-out in the analysis of longitudinal outcomes within randomized trials for Alzheimer’s Disease.  
Elizabeth Colantuoni, PhD1; Michael Rosenblum, PhD2; Jon Steingrimsson, PhD2; Aidan McDermott, PhD2; Arnold Bakter, PhD2; Michela Gallagher, PhD2,3

P22: An open-source implementation of data standards for Alzheimer’s Disease clinical trials  
Chung-Kai Sun, MS1; Michael Donohue, PhD1; Karin Ernstrom, MS1; Yanxin Jiang, MS1; Zeyun Lu, MS1; Paul Aisen, MD1; Rema Raman PhD1

P23: Longitudinal Impact of Audio Review on Data Quality  
Todd M. Solomon, PhD2, Jordan M. Barbone, BS1, Sarah M. Karas PsyD1, H. Todd Feaster PsyD1

P24: Utilizing Audio Review to Improve ADCS-ADL Data Quality  
Todd M. Solomon, PhD1, H. Todd Feaster PsyD1, Jordan M. Barbone, BS1 and David S. Miller, MD, MA1

P25: The influence of a mobility training program on gait performance among healthy cognitive elderly people and people with MCI  
Carine Federspiel, MD1,2, Elisabeth Bourkel, PhD1, Jean-Paul Steinmetz, PhD1,2

Late Breaking Posters

LBPI: Now I Remember! (That I’m in Another Study): Duplicate Subjects in Clinical Trials of Alzheimer’s Disease  
Thomas Shiovitz, MD2,3, Brittany Fox, BS1, Chelsea Steinmetz, BA1, Sabrina Schoneberg, BA1

LBP2: Alzheimer’s Disease should we jump, sink or swim through phase 2? How do different early phase designs address Alzheimer’s issues?  
Trevor Smart

LBP3: Low PET screen failure rate in the UB-311 Phase 2A study enriched for ApoE4 carriers with mild cognitive deficit  
Hui Chen Chen1, P. N. Wang2, M. J. Chiu, MD3, C. C. Huang4, C. C. Chang5, T. C. Yen6, K. J. Lin7, John Seibyl7, Jacob Hesterman8, Ajay Vermal,9

1United Neuroscience, Inc, Hauppauge, NY, USA; 2Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; 3Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan; 4Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; 5Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 6Department of Neurology, Taichung Chang Gung Memorial Hospital, Taichung, Taiwan; 7InviCRO LLC, Boston, MA, USA; 8Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; 9University of California, San Diego, CA, USA.
Wednesday, November 1 and Thursday, November 2

**LBP4**: The Brain Health Registry-IDEAS study: Evaluating the feasibility of Internet-based data collection in cognitively impaired older adults  
*Monica R Camacho1,2, Rachel L Nosheny PhD1,2, Shannon Finley MA1, Derek Flenniken1,2, Juliet Fochler1,2, R Scott Machin PhD1,3, Diana Truran-Sacrey1, Aaron Ulbricht1,2, J Wesson Ashford1,2, Curtis B Ashford3, Gil Rabinovici MD1, James Hendrix6, Maria Carrillo8, and Michael W Weiner MD2*

(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA (2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA (3) UCSF Department of Psychiatry, San Francisco, CA, USA (4) Stanford Department of Psychiatry & Behavioral Science, Palo Alto, CA, USA (5) Palo Alto Veteran’s Administration Medical Center, Palo Alto, CA, USA (6) MemTrax, Inc, Redwood City, CA, USA (7) UCSF Department of Neurology, San Francisco, CA, USA (8) Alzheimer’s Association, Chicago, IL, USA

**LBP5**: Frailty and biological ageing may impact the external validity of randomized controlled trials on Alzheimer’s disease.  
*Alessandro Trebbastoni1, Marco Canevelli1, Federica Quarata1, Fabrizia D’Antonio1, Matteo Cesari2, Giuseppe Bruno1 and Carlo de Lena1*

(1) Department of Neurology and Psychiatry, “Sapienza” University of Rome, Italy (2) Céramique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

**LBP6**: Clinical trial design of the CREAD Studies: randomized, double-blind, placebo-controlled, parallel-group Phase 3 studies to evaluate the efficacy and safety of crenezumab in patients with prodromal to mild Alzheimer’s disease  
*Helen Lin, MD 1, Janice Smith, PhD 2, Laurie Millar, PhD2, Kaycee M. Sink, MD 2, Mas6, Jillian Smith, BSc1, Andres Schneider, MD1, Reina Fuji, VMD, PhD1, Angelica Quatino, PhD1, Howard Machey, PhD1, Michael Rabbia, MA4, Susan Yule, B.Pharm1, Susanne Ostrowitzki, MD, PhD1, Paulo Fontoura, MD, PhD1, Rachelle Doody, MD, PhD1*

(1) Genentech, Inc, South San Francisco, USA; (2) Roche Products Ltd, Welwyn Garden City, UK; (3) F. Hoffmann-La Roche Ltd, Basel, Switzerland; (4) Roche Innovation Center New York, New York, NY

**LBP7**: Utilizing machine learning to enable improved cohort selection for Alzheimer’s Disease clinical trials  
*Mallory Busso BSc1, Emmanuel Fuentes BSc1, Christopher Buchley PhD2, Rabia Ahmad PhD2, Christopher Foley PhD2, Jan Wolber PhD2*

(1) GE Healthcare, Life Sciences, San Ramon, USA (2) GE Healthcare, Life Sciences, Core Imaging, Amersham, UK

**LBP8**: Does the Length of Time to Clinical Trial Site Activation Relate to Screening Performance?  
*Sarah Walter, MSc1, Devon Gessert, BS1, Elizabeth Shaffer-Bacareza, BS1, Karin Ernstom, MS1, Rema Raman, PhD1, Paul Aisen, MD1*

(1) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

**LBP9**: Next Generation of Clinical Development: Applying Patient-Centered Insights to Accelerate Patient Recruitment for Alzheimer’s Disease Clinical Trials  
*Olga Usopenshaya-Cadoz, MD, PhD2, Kenneth Stanley2, Natalia Balho1, Sadiq Lula1, Sam Khinda2, Milena Kanova, MD3, Penny Randall, MD3, Lynne Hughes2*

(1) QuintilesIMS Central Nervous System Center of Excellence (2) QuintilesIMS Project Leadership Unit (3) QuintilesIMS Analytics Center of Excellence

**LBP10**: Experimental Design on a Budget for Sparse Linear Models: Applications to Cognitive Patterns in Preclinical Alzheimer’s Disease  
*Daniel J. Belongia1, Sathya N. Ravi1, Rebecca Koscilt, PhD1, Erin Jonaitis, PhD1, Sterling C. Johnson, PhD2, Viktas Singh, PhD1*

(1) University of Wisconsin – Madison (2) William S. Middleton Memorial Veterans Hospital

**LBP11**: Rationale, Design and Progress of Alzheimer’s Prevention Initiative Trials  
*Pierre N. Tariot, MD, Jessica B. Langbaum, PhD, Eric M. Banner*

Alzheimer’s Institute, Phoenix, AZ, USA

**LBP12**: Graph Imputation techniques for estimating amyloid positivity from longitudinal cognitive and MRI measurements for efficient secondary prevention trials  
*Tuan Dinh, Sathyaa Ravi, Won-Iwa Kim, Nagesh Adluru, Rebecca Koscilt, Cynthia Carlsson, Sterling C. Johnson, Viktas Singh*

University of Wisconsin-Madison, WI, USA
**Theme 2. Clinical trials: Results**

**P26: Longitudinal cognitive and functional changes are influenced by educational history in the J-ADNI MCI individuals.**

Atsushi Iwata, MD, Takeshi Iwatsubo, MD, Kazuaki Suzuki, MD, Ryohito Ihara, MD, Hiroyuki Arai, MD, Kenji Ishii, MD, Michio Senda, MD, Kengo Ito, MD, Takeshi Ito, MD, Ryozo Kuwano, MD, Hiroshi Matsuda, MD for the Japanese ADNI

(1) Department of Neuropathology, The University of Tokyo, Tokyo, Japan (2) Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (3) Department of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan (4) National Center for Geriatrics and Gerontology, Obu, Japan

**P27: A randomized placebo-controlled cross-over trial investigating nabilone as a treatment for agitation in patients with advanced AD: study protocol**

Myuri Ruthirakuhan, PhD, Nathan Herrmann, MD, Nathan Herrmann, MD, Nathaniel Herrmann, MD, Elenor H. Abraham, BSc, Chelsea Sherman, BSc, Nicolaas Paul L.G. Verheoff, MD, FRCP, PhD, Alex Kiss, PhD, Sandra E. Black, MD, FRCPC, Ana C. Andreazza, PhD and Krista L. Lanctot, PhD

(1) Sunnybrook Research Institute, Toronto, ON, Canada (2) University of Toronto, Toronto, ON, Canada (3) Neuropsychopharmacology Research Group, Toronto, ON, Canada (4) Baycrest Health Sciences, Toronto, ON, Canada

**P28: BPN14770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer’s Dementia: Preclinical, PET Imaging and Human Phase I Results**

Mark Gurney, PhD, Chong Zhang, PhD, Ying Xu, PhD, James O’Donnell, PhD, Masashi Fujita, MD, PhD, Robert Innis, MD, PhD, Mark Gurney, PhD, Michael J. Lamson, PhD, Larry D. Alstiel, MD, PhD

(1) Tetra Discovery Partners, Inc. Grand Rapids, MI, USA (2) School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, USA (3) National Institute of Mental Health, Bethesda, MD, USA

**P29: Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease over 130 weeks: Results of Phase 3 Extension Study**


(1) Alzheon, Inc., Boston, MA, USA (2) University of Rochester, Rochester, NY (3) Palm Beach Neurology, Florida USA (4) University of Toulouse, Toulouse, France (5) McGill University, Montreal, Canada (6) Pharmapace Inc., San Diego, CA, USA

**P30: Effect of mild or moderate hepatic impairment on the clearance of azeliragon**

Ann Gooch, PhD, Aaron H. Burstein, PharmD, Scott J. Brantley, PhD, Michael J. Lamson, PhD, Imogene Dunn, PhD, Larry D. Alstiel, MD, PhD

(1) vTv Therapeutics, High Point, NC, USA (2) Nuventra Pharma Sciences, Inc, Durham, NC, USA

**P31: Effect of CYP2C8 and CYP3A4 inhibition and CYP induction on the pharmacokinetics of azeliragon.**

Aaron H. Burstein, PharmD, Michael J. Lamson, PhD, Mark Sale, MD, Scott J. Brantley, PhD, Ann Gooch, PhD, Imogene Dunn, PhD, Larry D. Alstiel, MD, PhD

(1) vTv Therapeutics, High Point, NC, USA (2) Nuventra Pharma Sciences, Inc, Durham, NC, USA

**P32: The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study**

Sharon J. Sha, MD, MS, Gayle K. Deutsch, PhD, Lu Tian, ScD, MSc, Kara Richardson, Maria Coburn, Jennifer Guadisoi, Tatiana Marcat, Ethan Solomon, MSc, Athanasia Bousis, Anthony Bitt, Steven P. Braithwaite, PhD, Sam Jackson, MD, MBA, Karolyn Niholich, PhD, Darby Stephens, Geoffrey A. Kerchner, MD, PhD, Tony Wyss-Coray, PhD, Aaron H. Burstein, PharmD

(1) Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA (2) Department of Health Research and Policy, Stanford University, Stanford, CA, USA (3) Department of Neurosurgery, Stanford University, Stanford, CA, USA (4) Department of Pediatrics, Stanford University, Stanford, CA, USA (5) Albert Einstein College of Medicine, Mount Sinai, New York, USA (6) University of Southern California, Los Angeles, CA

**P33: FUNDAMANT: a 72-week phase I follow-up study of AADVac1, an active vaccine against tau pathology**

Petr Novak, MD, PhD, Matej Ondrus, MD, MSc, Stanislav Katina, PaedDr, RNDr, Norbert Zilka, MVD, DrSc, Eva Kontsektova, RNDr, Prof, DrSc

(1) AXON Neuroscience CRM Services, SE, Bratislava, Slovakia (2) AXON Neuroscience R&D Services, SE, Bratislava, Slovakia
**P34: Open-Label Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease**

Lutz Frölich, MD1, Jose Luis Molinuevo, MD2, Alireza Atri, MD, PhD3, Clive Ballard, MD4, Neli Boneva, MD, PhD5, Marie Aavang Geist, PhD6, Anna Bladström, PhD6, Jeffrey L. Cummings, MD, ScD7, Pierre N. Tariot, MD8

(1) Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany, (2) Alzheimer's disease and other cognitive disorders unit, Neurology Service, ICN Hospital C. I. Universitari and Pasqual Maragall Foundation, Barcelona, Spain, (3) Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco, CA, USA, (4) Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, (5) University of Exeter Medical School, Exeter, UK, (6) St. Jude Children’s Research Hospital, Memphis, TN, USA, (7) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, (8) Banner Alzheimer’s Institute, Phoenix, AZ, USA

**Wednesday, November 1 and Thursday, November 2**

**P35: A Ketogenic Supplement Improves Brain Energy Metabolism and Cognition in Mild Cognitive Impairment: Preliminary Results of a 6-Month Randomized Controlled Study with Neuroimaging (BENEFIC TRIAL)**

Etienne Croteau, PhD1, Christian-Alexandre Castellano, PhD1, Melanie Fortier, MSc1, Francis Langlois, PhD1, Tamas Fulop, MD, PhD2, Stephen Cunnane, PhD3

(1) Research Center on Aging, CIUSSSSE – CHUS, Sherbrooke, QC, Canada, (2) Pharmacology-Physiology department, FMSS, University of Sherbrooke, QC, Canada, (3) Medicine department, FMSS, University of Sherbrooke, QC, Canada

**P36: MRI findings in the open label extension of the Marguerite RoAD study in patients with mild Alzheimer’s disease**

Danielle Abi-Saab, Psy.D1, Mirjana Andjelkovic, PhD2, Nathalie Pross, PhD2, Paul Delmar, PhD2, Nicola Voyle, PhD2, Nelli Esau1, Smiljana Ristic, MD1

(1) Hoffman La Roche, Basel, Switzerland, (2) Roche Products Limited, Welwyn, UK

**P37: Three Years of Treatment of the Trial on the Association between a Cholinesterase Inhibitor and Choline Alphoscerate in Alzheimer’s Disease: Interim Results**

Enea Traini, PhD1, Anna Carotenuto, PhD2, Angiola M Fasanaro, MD2, Valentino Manzo, MD2, Francesco Amenta, MD1

(1) Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino, (2) Alzheimer Evaluation Unit, National Hospital, “A. Cardarelli”, Naples, Italy

**P38: Safety and Efficacy Results from Phase 2 pilot trial of GM-CSF/Leultine® in mild-to-moderate AD**

Huntington Potter, PhD1, Jonathan H. Woodcock, MD2, Timothy Boyd, PhD2, Stefan H. Sillau, PhD2, Brianne M. Betcher, PhD2, Joseph Daniels1, Kate Hefferman1, and H. Gray2

(1) Rocky Mountain Alzheimer’s Disease Center, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, (2) CNIC Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, (3) Department of Neurosciences, University of Colorado School of Medicine, Aurora, CO, USA

**P39: Analysis of treatment emergent adverse event incidences in phase 2 study of azeliragon reveal potential attenuation of psychiatric system organ class (SOC) adverse events and expected drug effects in gastrointestinal SOC**

Imogene Dunn, PhD1, Aaron H Burstein, PharmD1, Larry D Altstiel, MD, PhD1

(1) VTV Therapeutics, High Point, NC, USA

**P40: Treatment with PXT-864 showed stabilisation of cognitive disability in mild Alzheimer’s disease after 36 weeks**

Jacques Touchon, MD PhD1, Pierre-Jean Ousset, MD2, Florence Pasquier, MD PhD3, Claude Guériot, MD4, Philippe Robert, MD PhD5, Sophie Auriaicome, MD1, Jean-Marc Orgogozo, MD, PhD6, Jacques Hugon, MD, PhD6, Peter Schmitt, PhD6, Anne-Claire Coyne, PhD7, Rodolphe Hajj, PhD7, René Goedkoop, MD8

(1) University Hospital Montpellier, France, (2) Alzheimer’s Disease Clinical Research Centre, Gérontopôle, Toulouse University Hospital, France, (3) Memory Clinic, Université Hospital Lille, France, (4) Memory Research (Resource Center for Alzheimer’s disease, University Hospital La Timone, Marseille, France, (5) Memory Clinic CHU-EA Cotrel, University of Nice Sophia Antipolis, Nice, France, (6) Memory Research Resource Center for Alzheimer’s disease, University Hospital Pellegrin, Bordeaux, France, (7) Memory Clinical Center CMMParis Nord ile-de-France, Saint Louis-Lariboisiere, Fernand Widal Hospital, AP-HP, Paris, France, (8) Pharmex SA, Issy-les-Moulineaux, France

**P41: Phase I Study of a Novel Humanized Anti-Amyloid beta (Aβ) Aggregates Specific Antibody KHH6640 in Alzheimer’s Disease**

Marc Cantillon, MD1, Louisa Wilson, MSc2, Eri Ohta, PhD3, Niels Prins, MD, PhD4, Niels Andreasen, MD, PhD5, Katsuyoshi Tsukii, MSc6

(1) Kyowa Kirin Pharmaceutical Development, Inc., USA, (2) Kyowa Kirin Pharmaceutical Development, Ltd, UK, (3) VLImc Alzheimer Center, Netherlands, (4) Karolinska University Hospital, Sweden

**P42: A Single Dose Study of a Novel Humanized Anti-Amyloid beta (Aβ) Aggregate Specific Antibody KHH6640 in Japanese Patients with Alzheimer’s Disease.**

Hiroyuki Shimada, MD, PhD1, Kenichiro Sugiyama, Pharm.B.S, Yoshiumi Ouchi, MEng2, Katsuyoshi Tsukii, MSc3

(1) Osaka city university hospital, Osaka, Japan, (2) Kyowa Hakko Kirin Co, Ltd, Japan, (3) Kyowa Kirin Pharmaceutical Development, Inc., USA
LBP25: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of AD-35 Tablets Taken Orally in Healthy Chinese Subjects
Cuibai Wei, PhD, MD, Jianping Jia, PhD, MD, Tingting Li, MS, Wei Wang, MD, Tingting Hou, MD, Xiu Wang, MD, Hui Xu, MD
(1) Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, P.R. China.

LBP26: The use of transdermal Rivastigmine in the treatment of Alzheimer’s disease
Gustavo Alves Andrade dos Santos
SENAC University Center, São Paulo, Brazil

LBP27: Title: NILVAD: A phase III clinical trial of nilvadipine in mild to moderate Alzheimer’s disease - results of subgroup analyses.
Michael Mullan, MBBS, PhD; Laila Abdullah, PhD; Fiona Crawford, PhD; Ricardo Segurado, PhD; Suzanne Hendrix, PhD; Brian Lawlor, MBBS.
The NILVAD consortium.
(1)Archer Pharmaceuticals, Sarasota, FL, USA; (2)University College Dublin, Dublin, Ireland; (3)Pentara Corporation, Soft Lake City, UT, USA; (4)Trinity College Dublin, Dublin, Ireland

LBP28: Biomarker Outcomes from the Phase Ib/2a Safety Trial of the Anti-β Oligomer Drug CT1812 in Alzheimer’s Patients
Susan M. Catalano, PhD; Lon S Schneider, MD, MS; Steven DeKoshy, MD; Roger Morgan, MD; Courtney Rehahl; Kelsie Mozzeni; Nicholas J Izzo, PhD; Michael Grundman, MD, MPH; Michael Schirm, PhD; Rudolf Guibaud, MSC; Daniel Chehsky, PhD
(1)Cognition Therapeutics Inc., Pittsburgh, PA, USA; (2)Global R&D Partners, LLC, San Diego, California USA; (3)Keck School of Medicine of USC, Los Angeles, CA, USA; (4)McKnight Brain Institute, University of Florida, Gainesville, FL, USA; (5)MedSurgePI, LLC Raleigh, North Carolina, USA; (6)Aclairo Pharmaceutical Development Group, Inc. Vienna, VA USA; (7)Caprion Biosciences, Inc., Montreal, Canada

LBP29: UB-311 active vaccine generates titers specific for Aβ oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase I and an ongoing Phase 2a study in Alzheimer’s disease.
Ajay Verma1, Paul Maruff2, A. Schembri2, P. N. Wang3, M. J. Chu4, C. C. Huang5, C. C. Chang6, H. C. Chen1, P. Chang1, C. Y. Wang1
(1)United Neuroscience, Inc. Hauppauge, NY, USA; (2)Cogstate Limited, Melbourne, Victoria, Australia; (3)Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; (4)Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan; (5)Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; (6)Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

LBP30: Multiparameter Analyzes of Progression from Mild Cognitive Impairment to Alzheimer’s Dementia: A 10 Year long-term Follow-Up Study
Oliver Peters MD1; Dominik Diesing MD2; Stefan Klöppel MD2; Johannes Komhuber MD3; Roberto Goya MD4; Jens Willfang, MD5; Isabella Heuser, MD, PhD
(1)Department of Psychiatry, Charité, Berlin, Germany; (2)Department of Psychiatry, Bern, Switzerland; (3)Department of Psychiatry, Erlangen, Germany; (4)Department of Psychiatry, Göttingen, Germany

LBP31: Single Ascending Dose Phase I clinical trial of PTI-125 in healthy volunteers
Lindsay H. Burns, PhD1; George J. Atiee, MD, PhD2; Michael Marsman, PharmD1
(1)Pain Therapeutics, Inc., Austin, TX; (2)Worldwide Clinical Trials, San Antonio, TX

LBP32: Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy
Irfan Qureshi, MD1; Michael Grundman, MD, MPH2; Giridhar Tirucherai, PhD3; Clifford Bechtold, MS1; Michael Ahljanian, PhD1; Gerry Kolaitis, MS1; Lawrence I. Golbe, MD3; Lawrence S. Honig, MD, PhD4; Stuart Isaaco, MD5; Murray Grossman, MD EdD6; Nikolaus R. McFarland, MD, PhD7; Irene Litvan, MD, PhD; David S. Geldmacher, MD8; Tao Xie, MD, PhD9; Yvette Borelon, MD, PhD10; Paul Tuite, MD11; Padraig O’Suilleabhain, MD12; Theresa Zesiewicz, MD13; Adam Boxer, MD, PhD14
(1)Bristol-Myers Squibb, Lawrenceville, NJ, USA and Wallingford, CT, USA; (2)Global R&D Partners, LLC, San Diego, CA, USA; (3)Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; (4) Columbia University Medical Center, New York, NY, USA; (5)Boca Raton Institute for Neurodegenerative Disorders, Boca Raton, FL, USA; (6)University of Pennsylvania, Philadelphia, PA, USA; (7)University of Florida, Gainesville, FL, USA; (8)University of California, San Diego, CA, USA; (9)University of Alabama at Birmingham, Birmingham, AL, USA; (10)University of Chicago, Chicago, IL, USA; (11)University of California, Los Angeles, CA, USA; (12)University of Minnesota, Minneapolis, MN, USA; (13)University of Texas Southwestern Medical Center, Dallas, TX, USA; (14)University of South Florida, Tampa, FL, USA; (15)University of California, San Francisco, CA, USA
Theme 11. New therapies and clinical trials

P114: A novel approach to the therapy of Alzheimer’s disease based on peptide nanoliposome inhibitors of Aβ and tau aggregation
David Allsop, PhD1,2, Mark Taylor, PhD1,2, Nigel Fullwood, PhD1, Maria Michael1, Anthony Aggidis1, Shooana Vincent, PhD1, Mark Dale, MD2
(1) Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK (2) Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

P115: Alzheimer’s disease drug development pipeline: 2017
Jeffrey Cummings1, Garam Lee1, Travis Mortsdorf1, Aaron Ritter1, Kate Zhong1
(1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA (2) Touro University Nevada, Henderson, NV, USA (3) Global Alzheimer Platform, Washington, D.C., USA

P116: The influence of a mobility training program on gait performance among healthy cognitive elderly people and people with MCI
Carine Federspiel, MD1,2, Elisabeth Bourtel, PhD1, Jean-Paul Steinmetz, PhD1,2
(1) Centre for memory and mobility, Luxembourg (2) ZithaSenior, Research & Development, Luxembourg

P117: Pre-clinical and first clinical data of an orally available amyloid beta oligomer eliminating compound that enhances cognition and impedes neurodegeneration in various Alzheimer’s disease mouse models
Dieter Willbold1,2, Janine Kutzsche1, Manfred Windisch3, Dagmar Jürgens2
(1) Institut für Physikalische Biologie, Heinrich-Heine-Universität, Düsseldorf, Germany (2) Institute of Complex Systems, ICS-6: Structural Biochemistry, Research Centre Jülich, Jülich, Germany (3) Neuroscios, Graz, Austria

P118: Informed Consent Ensuring Access to Anonymized Patient-Level Data and Biospecimen is Critical to Accelerating Innovative Alzheimer Disease Treatments
Stephen P. Arnerić, PhD1, Penny A. Dachs, PhD2, Ann Marie Hahe, MD3, James Hendrix, PhD4, Monica Moreno5, Lisa A. Gold, PhD6, Dagmar Theis, PhD7, Mark F. Gordon, M.D.8, Volter D. Kern, PhD9, George Vradenburg10
(1) Critical Path Institute, Tucson, AZ, USA (2) American Epilepsy Society, Chicago, IL, USA (3) Eli Lilly and Company, Indianapolis, IN, USA (4) Alzheimer’s Association, Chicago, IL, USA (5) Merck, West Point, PA, USA (6) Boehringer-Ingelheim, Vienna, Austria (7) Advisor, CT, USA (8) USA Against Alzheimer’s, Washington, DC, USA

P119: Novel strategies against Alzheimer’s Disease using induced human neuronal progenitors and neuronal cells
Ying Lei, PhD1, Gang Li, MD, PhD1, Ying Chen, PhD1, Ge Gao, MD, PhD1 and Jian Zhao, PhD1
(1) GMP Center of Stem Cell Engineering, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China (2) iCell Biotechnology Co., Ltd, Shanghai, China

P121: P38α kinase inhibition appears to lead to reduction in amyloid-beta generation in patients with Early Alzheimer’s disease
Philip Scheltens MD PhD1, Niels Prins MD PhD1, Adriaan Lammertsma PhD2, Maqsood Yaqub PhD2, Hui-May Chu PhD2, Bart van Berckel MD PhD2, John Alam MD3
(1) Department of Neurology and Alzheimer’s Center, VU University Medical Center; and the Alzheimer’s Research Center (ARC), Amsterdam, NL (2) Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, NL (3) Anoixis Corporation, Natich, MA, USA (4) EIP Pharma LLC, Cambridge, MA, USA

P122: ACD678, A novel gamma-secretase modulator for the treatment of Alzheimer Disease
Bengt Winblad1, Johan Lundkvist2, Helena Karlström1, Magnus Halldin1, Johan Sandin2, Gunnar Nordvall2
(1) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden (2) AlzeCare Pharma AB, Huddinge, Sweden
**P123:** Demonstration of blood-brain-barrier (BBB) penetration and brain target engagement for neflamapimod (p38α kinase inhibitor) in patients with early Alzheimer’s disease (AD)

John Alam¹, Charlotte Teunissen²

(¹) EIP Pharma LLC, Cambridge, MA, USA (²) Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL

**P124:** ACD855, development of a positive modulator of neurotrophin signaling for the treatment of Alzheimer’s Disease

Pontus Forsell, PhD², PhD, Gunnar Nordvall², PhD, Johan Lundtwist², PhD, Magnus Halldin², PhD, Märta Dahlström⁽³⁾, M.Sc. and Maria Eriksdotter⁽⁴⁾, MD, Prof, and Johan Sandin⁽²⁾, PhD

(¹) AlzeCure Foundation, Karolinska Institutet Science Park, Huddinge, Sweden (²) AlzeCure Pharma AB, Huddinge, Sweden (³) Dept of Neurobiology, Care Sciences and Society, Karolinska Institutet, Sweden (⁴) Dept Geriatric Medicine, Karolinska university hospital, Huddinge, Sweden

**P125:** Pharmacokinetics and Delivery to the Brain in Rats of P8, a Peptide Drug Candidate for the Treatment of Alzheimer’s Disease

Nazneen N. Dewji¹,², S. Jonathan Singer¹,³, Leah Hanson⁴, William Frey⁵, Bruce Morimoto⁶, David Johnson⁷, Daniel Dolan⁶, Marc R. Azar⁷

(¹) Cenna Biosciences Inc., La Jolla, CA, USA (²) Department of Medicine, UC San Diego, La Jolla, CA, USA (³) Division of Biological Sciences, UC San Diego, La Jolla, CA, USA (⁴) Health Partners Institute, St. Paul, MN, USA (⁵) Celerion Inc., USA (⁶) MicroConstants, San Diego, CA, USA (⁷) Behavioral Pharma, La Jolla, CA, USA

**P126:** The ABCA-1 agonist CS6253 that reverses apoE4-driven Alzheimer’s disease brain phenotype and cognition decline lowers plasma Neurofilament-light concentrations.

Jan O Johansson¹, Anat Boehm-Cagan¹, Henrik Zetterberg³, Kaj Blennow²,⁵, John K. BIELICKI¹, Daniel M. Michaelson²

(¹) Artery, Therapeutics, Inc., San Ramon, CA; (²) Tel Aviv University, Tel Aviv, Israel; (³) Department of Psychiatry and Neurochemistry, (⁴) Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; (⁵) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; (⁶) Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute, London, UK; (⁷) UC Berkeley, Berkley, CA

**P127:** Novel modulators of molecular chaperone network for the treatment of Alzheimer Disease

Pavel Pavlov PhD, Bengt Winblad MD, PhD, Rajnish Kumar PhD

Karolinska Institutet, Dept of Neuroscience and Society, Div of Neurogeriatrics, Huddinge, Sweden

**P128:** Cerebral Energy Deficit in Mild to Moderate Alzheimer’s Disease: Strategies to Increase Brain Fuel Supply

Christian-Alexandre Castellano, PhD², Etienne Croteau, PhD², Melanie Fortier, MSc³, Christian Boci³, MD³, Tamas Fulop, MD⁴, Guy Lacombe, MD³, Nancy Paquet, MD⁵, Isabelle Dionne, PhD⁶ and Stephen Cunnane, PhD⁶

(¹) Research Center on Aging, CIÚSSS – CHUS, Sherbrooke, QC, Canada (²) Pharmacology-Physiology department, FMSS, University of Sherbrooke, QC, Canada (³) Medicine department, FMSS, University of Sherbrooke, QC, Canada (⁴) Nuclear medicine department, FMSS, University of Sherbrooke, QC, Canada (⁵) Faculty of physical education and sports, University of Sherbrooke, QC, Canada

**P129:** Pharmacokinetic and target engagement (TE) analysis of BIIB076 in cynomolgus monkeys

Weiping Chen, Julie Czerniowicz, Qin Wang, Danielle Graham

Biogen Inc. Cambridge, MA, USA

**Late Breaking Posters**

**LBP15:** SUVN-502 + Donepezil + Memantine (Triple combination) represents a promising new approach for symptomatic treatment of Alzheimer’s disease.

Ramakrishna Nirogi, PhD¹, Renny Abraham, PhD¹, Vijay Benade, MS¹, Pradeep Jayarajan, PhD¹, Koteshwar Mudigonda, PhD¹, Jyothsna Raval, MS¹, Devender Reddy Ajjala, PhD¹, Ramasasstry Kambhampati, PhD¹, Trinath Reddy Bandyala, PhD¹ and Venkat Jasti MS¹

(¹) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**LBP16:** Neuroprotective and trophic effects of Bacopa monniera extract protects against amyloid β-peptide and hydrogen peroxide-induced toxicity and oxidative stress

Manjeet Singhi and Charles Ramassamy¹

(¹) INS- Institute Armand Frappier, Laval, Quebec, Canada
LBP17: Phase I Study of the Muscarinic M1 Positive Allosteric Modulator VU319 for Alzheimer’s Disease: Exploration of Novel Markers of Target Engagement

Paul A Newhouse, MD, PhD1, Alexandra Key, PhD2, Alexander Conley, PhD1, Robert Gould, PhD3, Carrie Jones, PhD1
1. Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center (2) Vanderbilt Kennedy Center, Vanderbilt University (3) Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University

LBP18: Efficacy and safety of the Chinese medicine SaiLuoTong in vascular dementia: A randomised, controlled, double-blind, parallel-arm trial

Jianqing Jia1,2,3,4,5, M. D., Ph. D., Cuibai Wei, M. D.1,4, Shuqi Chen, M. D.1, Fangyu Li, M. D.1, Yi Tang, M. D.1, Lu Shi, M. D.1, Min Gong, M. D.1, Hui Xu, M. D.4, Fang Li, M. D.6, Jian He, M. D.7, Haiqing Song, M. D.7, Shanshan Yang, M. D.8, Aihong Zhou, M. D.1, Fen Wang M. D.1, Xiumei Zuo, M. D.1, Changbiao Chu, M. D.1, Junhua Liang, M. D.1, Longfei Jia, M. D.1, Serge Gauthier, M. D.10
1. Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China (2) Beijing Key Laboratory of Genomic Cognitive Disorders, Beijing, China (3) Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China (4) Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China (5) National Clinical Research Center for Geriatric Disorders, Beijing, China (6) Department of Gerontology, Fuxing Hospital, Capital Medical University, Beijing, China (7) Department of Health Statistics, Second Military Medical University, Shanghai, China (8) Department of Neurology, Daping Oilfield General Hospital, China (9) Department of Neurology, Henry Ford Hospital, Detroit, USA (10) Centre for Studies in Aging, McGill University, Montreal, Canada

LBP19: Increased immune signaling predicts mitigation in AD clinical outcomes – an alternate route to prevention.

John Breitner, MD, MPH (1) Douglas Hospital Research Centre, Montreal, QC, Canada (2) McGill University Faculty of Medicine

LBP20: CHARACTERISTICS OF SLEEP AND WAKEFULNESS MEASURED WITH ACTGRAPHY IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE.

Margaret Moline, PhD1, Patricia Murphy, PhD1, Gleb Filipov, MD, PhD1, Naoki Kubota, MPHarm2, Mohammad Bsharat, PhD1, Manuel Kemethofer, MSc3, Andrew Satlin, MD1
1. Eisai, Inc., Woodcliff Lake, NJ, USA (2) Eisai Co., Ltd. Tokyo, Japan (3) The Siesta Group, Vienna, Austria

LBP21: MULTIPLE ASCENDING DOSE STUDY WITH A PRODRUG OF GALANTAMINE: A PHARMACO-EEG ANALYSIS WITH EVIDENCE OF POSITIVE EFFECTS ON COGNITION.

D.G. Kay PhD1, E. ‘Hart PhD2, C. Bakker MD1, A. Maeliche PhD3, Sonja Simpraga4, Klaus Linkenhaer-Hansen5, Simon-Shlomo Poli6, G.J. Groeneveld MD PhD7, 1. Neurodyn Cognition Inc., Charlottetown, PE, Canada (2) Centre for Human Drug Research (CHDR), Leiden, the Netherlands (3) Galantos Pharma, Nieder-Olm, Germany (4) Vrije Universiteit Amsterdam, the Netherlands (5) NBT Analytics BV, Amsterdam, the Netherlands

LBP23: Matrix therapy, a novel approach for Alzheimer’s disease and related tauopathies

Dulce Papy-Garcia, PhD1 Growth, Repair and Regeneration of Tissues Research Unit (CRRET-CNRS 9215, Université Paris Est Créteil, Créteil, France Mohand-Ouidir Ouidja, PhD1,2; Fernanda Sineriz, PhD2, Denis Barritault, PhD3
1. CRRET-CNRS 9215, Université Paris Est Créteil, Créteil, France (2) OTR3, Paris, France

LBP24: ALLOPREGNANOLONE AS A REGENERATIVE THERAPEUTIC FOR ALZHEIMER’S DISEASE: PHASE IB/2A OUTCOMES

Roberta Diaz Brionto, PhD1, Gerson Hernandez, MD2, Christine Solinsky, PharmD3, Meng Law, MD3, Yonggang Shi, PhD5, Dogu Aydogan, PhD2,3, Jim Gahn, PhD3, Wendy Mach, PhD6, Naoko Kono, MPH7, Kathleen Rodgers, PhD3, Claudia Lopez2, Ronald Irwin, PhD4, Michael Rogawaki, MD1, Chun-Yi Wu, PhD2, Lon Schneider, MD3, 1. Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (2) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (3) Department of Clinical & Experimental Therapeutics, University of Southern California, Los Angeles, CA, USA (4) Department of Neuromedical Imaging and Informatics, University of Southern California, Los Angeles, CA, USA (5) Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (6) Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (7) Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (8) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA (9) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA (10) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (11) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (12) Department of Pharmacology, University of Southern California, Los Angeles, CA, USA (13) Department of Neurology, University of California at Davis, Davis, CA, USA (14) Department of Neurology, University of California at Davis, Davis, CA, USA (15) Department of Psychiatry, University of Southern California, Los Angeles, CA, USA
POSTER PRESENTATIONS

Friday, November 3 and Saturday, November 4

Theme 3. Clinical trials: Imaging

P43: France adopts a 3D diagnosis strategy for its National Alzheimer databank – An optimization of patient selection for clinical trials
Pierre Krolak-Salmon, MD, PhD, Philippe Robert, MD, PhD, Eric Assemani, MD, Claudine Bert, PhD, Mathieu Ceccaldi, MD, PhD, Bruno Dubois, MD, PhD, Stéphane Épelbaum, MD, PhD, Bruno Vellas, MD, PhD, Audrey Gabelle, MD, PhD
(1) Clinical and Research Memory Centre of Lyon, Hospices civils de Lyon, University Lyon 1, INSERM U1028, UMR CNRS 5292, Lyon, France (2) Clinical and Research Memory Centre of Nice, France (3)Memory Clinic Alpes Nord, France (4)Inserm U106, University of Montpellier, 34093 Montpellier, France (5)Clinical and Research Memory Centre of Marseille, France (6)Clinical and Research Memory Centre of Paris Plate-Salpetrière, France (7)Clinical and Research Memory Centre of Toulouse, France (8)Clinical and Research Memory Centre of Montpellier, France

P44: Divergent topological networks of grey and white matter in Alzheimer’s disease: A diffusion kurtosis imaging analysis
Jun Xu, Hongying Zhang, Jiaxing Cheng
(1) Neurology Department, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, China (2) Radiology Department, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, China

P45: Impact of two distinct MRI parallel imaging implementations on hippocampal volume estimates obtained from two methodologically different methods
Oliver Peters, MD, Per Suppa, Catharina Lange, MSC, Ralph Buchert, PhD, Lothar Spies, PhD, Isabella Heuser, MD, PhD
(1) Department of Psychiatry, Charité, Berlin, Germany (2) Jung Diagnostics GmbH, Hamburg, Germany (3) Department of Nuclear Medicine, Charité, Berlin, Germany (4) Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Germany

P46: MRI markers of neurodegeneration in preclinical Alzheimer’s disease
Adam J. Schwarz, MD, Michael G. Case, MS, Per Suppa, Catharina Lange, MSc, Ralph Buchert, PhD, Brian Willis, PhD, Wenping Wang, PhD, Richard Novak, MD, Brian Corrigan, PhD, Timothy Nicholas, PhD, Danny Chen, PhD, Julie Stone, PhD, Vitrak Sinha, PhD, Brian Willis, PhD, Wenping Wang, PhD, Stephen P. Arneric, PhD
(1) Critical Path Institute, Tucson, AZ, USA (2) University of California, San Diego, CA, USA (3) Johns Hopkins University, Baltimore, MD, USA

P47: FDA Qualification of Intracranial Adjusted Hippocampal Volumetric Magnetic Resonance Imaging (ICV-HV vMRI) as a Prognostic Biomarker for Pre-Dementia Clinical Trials for Alzheimer disease Therapeutics
Daniela J. Conrado, PhD, Klaus Romero, MS, MD, Derek L. Hill, PhD, Patricia Cole, MD, PhD, Dawn Matthews, PhD, Gerald Novalt, MD, Volker D. Kern, PhD, Robin Wolz, PhD, Richard Meibach, PhD, Jackson Burton, PhD, Brian Corrigan, PhD, Timothy Nicholas, PhD, Danny Chen, PhD, Julie Stone, PhD, Vitrak Sinha, PhD, Brian Willis, PhD, Wenping Wang, PhD, Stephen P. Arneric, PhD
(1) Critical Path Institute, Tucson, AZ, USA (2) University of California, San Diego, CA, USA (3) Advisor, MA, USA (4) Advisor, NJ, USA (5) Advisor, IN, USA

P48: Cerebral Atrophy in Alzheimer’s Disease Patients: Effect of Combined Therapy Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor, Choline Alphasecrae
Enea Traini, PhD, Anna Carotenuto, PhD, Angiola Maria Fasanaro, MD, Francesco Amenta, MD
(1) Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino, Italy

P49: Cerebral hypoperfusion is not associated with an increase in β-amyloid pathology
Ruben Smith, MD, PhD, Sebastian Palmqvist, MD, PhD, Hanna Ljung, MS, Tobias Cronberg, MD, PhD, Danielle van Westen, MD, PhD, Ostar Hansson, MD, PhD
(1) Lund University, Clinical Memory Research Unit, Dept. of Clinical Sciences Malmö, Malmö, Sweden (2) Skåne University Hospital, Dept. of Neurology, Lund, Sweden (3) Lund University, Skåne University Hospital, Dept. of Clinical Sciences, Neurology, Lund, Sweden (4) Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Diagnostic Radiology, Lund, Sweden (5) Skåne University Hospital, Memory clinic, Malmö, Sweden

P50: Optimized detection of disease and treatment effect in preclinical and prodromal autosomal dominant Alzheimer’s disease with imaging biomarkers
Dawn C Matthews MS MM, Ana S Lubicz PhD, Randolph D Andrews MS, Miles N Wernick PhD, Stephen C Strother PhD, Tammie L S Benzinger MD PhD, Dominantly Inherited Alzheimer Network
**Poster Presentations**

Friday, November 3 and Saturday, November 4

**P51: Cognitive Function and Prevalence of Amyloid Pathology in Frail Adults – The COGFRAIL Study**

Sourdet S, MD, Soriano G, RD, Steinmeyer Z, MD, Delrieu J, MD, Ousset PJ, MD, Vellas B, MD, PhD.

(Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.)

**P52: Hippocampal volume is weakly associated with amyloid beta levels in asymptomatic individuals at risk for Alzheimer’s disease: findings from the CHARIOT-PRO Sub-Study**


(Kanssen Neuroscience LLC, California, USA) (2)Kanssen Neuroscience LLC, New Jersey, USA (3)Neuropediatrics and Ageing Research, Imperial College London, London, UK (4)MedAvante Inc., New Jersey, USA

**P53: Impact on Sample Size and Screening Using Amyloid Visual Read versus Quantitative Values for Inclusion**

Donald G. McLaren, PhD, Felix Carbone, PhD, Alex P. Zijdenbos, PhD, Barry J. Bedell, MD, PhD.

(Biospective Inc., Montreal, Quebec, Canada (2) McGill University, Montreal, Quebec, Canada)

**P54: Automated voxel-based Tau PET quantitation in early Alzheimer’s Disease: Association of hippocampus masked SUVR with baseline cognition**

Arthur Mikhno, PhD, Janos Redei, MD, PhD, John Mann, MD, Ramin Parsley, MD, PhD.

(Biospective Inc., San Francisco, CA, USA) (2) Columbia University, New York, NY, USA (3) New York State Psychiatric Institute, New York, NY, USA (4) Stony Brook University, Stony Brook, NY, USA

**P55: Inter and Intra PET Scanner Variability in Multi-Center Clinical Trials Using the Hoffman Phantom**

Katarzyna Adamczuk, PhD, Beth Gorman, BS CNMT, Maureen Runtle, BS CNMT, Nicolas Pannetier, PhD, David Scott, PhD, Joyce Suhy, PhD.

(Bioclinica, Newarth, CA, USA; 2)Bioclinica, Philadelphia, PA, USA

**Late Breaking Posters**

**LBP35: CROSS-SECTIONAL ASSOCIATIONS BETWEEN TAU PATHOLOGY BURDEN MEASURED BY [18F]GTP1 PET IMAGING AND COGNITION IN AD**

Michael Ward, PhD, Sandra Sanabria Bohorquez, PhD, Paul T. Manser, PhD, Edmond Teng, MD PhD, Gai Ayalon, PhD, Kristin R. Wildsmith, PhD, Geoffrey A. Kerchner, MD, PhD, Robby M. Weimer, PhD.

(1) Early Clinical Development, (2) Clinical Imaging Group, (3) Biomarker Development; all Genentech, Inc., South San Francisco, CA, USA

**LBP36: Retinal Hyperspectral Imaging for Early Diagnosis of Alzheimer’s Disease**

Swati S. More, James M. Beach, Robert Vince

Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN

**LBP37: Simplified Non-Invasive Tracer Kinetic Analysis for 18F-Florbetaben PET using a Dual Time-Window acquisition protocol**

Andrew W. Stephens, MD, PhD, Henryk Barthel, MD, PhD, Santiago Bullich, PhD, Norman Koglin, PhD, Georg A. Becker, PhD, Aleksandar Jovanetic, PhD, Susan De Santi, PhD, Osama Sabri, MD, PhD.

(1) Piramal Imaging GmbH, Berlin, Germany (2) Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany (3) Piramal Pharma Inc., Boston, MA, USA

**LBP38: Voxel-wise determination of thresholds for amyloid and tau positivity using PET may improve the population enrichment of clinical trials**

Tharick A. Pascoal MD, Sulantha Mathotaarachchi MSc, Min Su Kang BSc, Joseph Titheriault, Monica Shin MSc, Andrea L. Benedet MSc, Sara Mohades BSc, Jean-Paul Soucy MD, MSc, Serge Gauthier MD, FRCPC, and Pedro Rosa-Neto MD, PhD for the Alzheimer’s Disease Neuroimaging Initiative.

(1) Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Alzheimer’s Disease Research Unit, Douglas Hospital, McGill University, Montreal, Canada. (2) Department of Neurology and Neurosurgery, McGill University, Montreal, Canada. (3) Montreal Neurological Institute, Montreal, Canada. (4) PERFORM Centre, Concordia University, Montreal, Canada.)
Friday, November 3 and Saturday, November 4

Theme 4. Clinical trials: Biomarkers including plasma

**P56:** Development of computational tools to improve the design of clinical trials of possible therapies for Alzheimer’s disease
Christoforos Hadjichrysanthou, PhD1, Alison Ower, MSc1, Stephanie Evans, PhD1, Kevin McRae-McKee, MSc1, Mei Mei Wong, PhD1, Frank de Wolf, MD, PhD1, Roy M. Anderson, PhD2
(1) Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom (2) Janssen Prevention Center, Leiden, The Netherlands

**P57:** PiB-PET as a standard for evaluating the clinical accuracy of diagnosing the clinical diagnosis of Alzheimer’s disease with plasma biomarkers
Che-Chuan Yang, PhD1,2, Ta-Fu Chen, MD, PhD3, and Shieh-Yueh Yang, PhD1
(1) MagQu Co., Ltd, New Taipei City, Taiwan (2) Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, , Taiwan

**P58:** A cross-validation study on plasma biomarker detection in clinical practice for diagnosing Alzheimer’s disease
Ming-Jang Chiu, MD1,2, Ta-Fu Chen, MD, Chaur-Jong Hu, MD3, Sui-Hing Yan, MD3, Yu Sun, MD3, Bing-Hsien Liu, PhD3, Yun-Tsui Chang, MS3, Che-Chuan Yang, PhD1, and Shieh-Yueh Yang, PhD3
(1) Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan (2) Department of Neurology, Taipei Medical University, Shuang-Ho Hospital, New Taipei City, Taiwan (3) Department of Neurology, Renai Branch, Taipei City Hospital, Taipei, Taiwan (4) Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan (5) MagQu Co., Ltd, New Taipei City, Taiwan

**P59:** Brain ABCA-1 activity and APOE lipidation are reduced in APOE4 and with cognitive impairment.
(1) USC, Los Angeles, CA; (2) Tel Aviv Univ, Herzliya, Israel; (3) Huntington Med Res Inst, Pasadena, CA; (4) Artery Therapeut, San Ramon, CA; (5) UC Berkeley, Berkeley, CA; (6) Tel Aviv Univ, Tel Aviv, Israel

**P60:** Analysis of Macular thickness and retinal nerve fiber layer by using of spectrum domain-optical coherence tomography in patients with Alzheimer’s disease and amnestic mild cognitive impairment
Kyung-Hoon Shin, MD1, Do-Gyun Kim, MD, PhD2, Bon D Ku, MD3
(1) Department of Ophthalmology, Kim’s Eye’s Hospital, Konyang University, South Korea (2) Department of Ophthalmology, Myongji Hospital, Seonam University College of Medicine, South Korea (3) Department of Ophthalmology, International St. Mary’s Hospital Institute for Translational & Clinical Research College of Medicine Catholic Kwandong University, South Korea

**P61:** Levels of cerebrospinal fluid biomarkers total tau and phosphorylated tau do not predict survival time after diagnosis of Alzheimer’s disease – An 18-year follow-up
Catrina Watimo, RN, BSc, PhD1,2, Mark Pets, PhD1, Lennart Minthon, MD, PhD2, Oskar Hansson, MD, PhD2
(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden (2) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy, University of Gothenburg, Malmö, Sweden

**P62:** An Amyloid Blood Biomarker for Preclinical Alzheimer’s Disease
Klaus Genwent, Prof, PhD1, Andreas Nabers, PhD1, Julia Lange1, Jonas Schartner, PhD1, Jörn Güldenhaupt, PhD1
(1) Department of Biophysics, Ruhr-University Bochum, Germany

**P63:** Effects of APOE4 on neuroimaging, biomarkers and clinical characteristics of prodromal Alzheimer’s disease
Niklas Matsson, MD, PhD1,2,3, Oscar Eriksson, MD1, Olof Lindberg, PhD1, Michael Schöll, PhD1, Björn Lampinen, PhD1, Markus Nilsson, PhD1, Philip S. Insell1,7,8, Ronald Lautner, MD1,2, Olof Strandberg, PhD1, Danielle van Westen, MD, PhD1, Henrik Zetterberg, MD, PhD1,2,3, Kaj Blennow, MD, PhD1,2, Sebastian Palmqvist, MD, PhD1,2, Erik Stomrud, MD, PhD1,2, Oskar Hansson, MD, PhD1,2
(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden (2) Department of Neurology, Skåne University Hospital, Lund, Sweden (3) MedTech West and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Malmö, Sweden (4) Clinical Sciences Lund Medical Radiation Physics, Lund, Sweden (5) Clinical Sciences Lund Radiodiagnostic Radiology, Lund, Sweden (6) Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Diagnostic Radiology, Lund, Sweden (7) Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA (8) Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA (9) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Malmö, Sweden (10) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Malmö, Sweden (11) Department of Molecular Neuroscience, UCL Institute of Neurology
P64: Low Total Aβ42/40 Plasma Ration in MCI Patients is Associated with a FDG-PET Pattern Suggestive of AD and Predicts Progression to Dementia.
Virginia Pérez-Grialba1, Judith Romerol1, Pedro Pesina1, Leticia Sarasa1, Itziar San-José1, Javier Arbizu2, Lluis Tarraga3, Agustín Ruiz2, Mercé Boada4, Manuel Sarasa1 and The AB25S Aracron Groupa
(1)Aracron Biotech S.L., Zaragoza, Spain (2) Clinica Universitaria de Pamplona, Pamplona, Spain (3) Alzheimer Research Center and Memory Clinic, Fundación ACE. Institut Català de Neurociències Aplicades. Barcelona, Spain (4) www.aracron.com

P65: Beta Amyloid Anti-Oligomer Action of ALZ-801 and Clinical Dose Translation Analyses Support Confirmatory Phase 3 Program in Alzheimer’s Disease
JA HEY, PhD1, P KOCIS, PhD2, S ABUSHAKRA, MD3, J YU, MD, PhD4, A POWER, MD5, K BLENNEW, MD6, M TOLAR, MD, PhD6
(1)Alzheon Inc., Framingham, MA, USA, (2)University of Gothenburg, Molndal, Sweden

P66: Elecsys CSF Biomarkers Predict pre-dementia and Cognitive Outcomes
Chenqie Xiong1,2,3,4 PhD, Dean Coblé1, PhD, Julia D. Gray2,3,4, BS, Elizabeth Grant1,2, PhD, Lena McCue1,2, PhD, John C. Morris2,3, MD, Jason Hassenstab4,5, PhD, Richard Batla6, PhD, Udo Eichenlaub7, MD, Eugeen Vanmechelen, PhD1
(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (2)Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA (3)Department of Preventive Medicine, Washington University School of Medicine, St. Louis, MO, USA (4) Department of Mathematics, Washington University, St. Louis, MO, USA (5) Roche Diagnostics international, (Rothenz, Switzerland (6) Roche Diagnostics GmbH, Penzberg, Germany (7) Roche Diagnostics Operations, Indianapolis, IN, USA

P67: The evaluation of novel monoclonal antibodies targeting different forms of Neurofilament Light in brain and CSF
J.A. HEY, PhD1, P. KOCIS, PhD1, S. ABUSHAKRA, MD4, J. YU, MD, PhD4, A. POWER, MD5, K. BLENNEW, MD5, M. TOLAR, MD, PhD5
(1)ADx NeuroSciences N.V., Gent, Belgium (2) Charité-Universitätsmedizin Berlin, Memory Clinic at the ECRC, Berlin, Germany

P68: Elecsys CSF Biomarkers Predict Clinical and Cognitive Outcomes
Chenqie Xiong1,2,3,4 PhD, Dean Coblé1, PhD, Julia D. Gray2,3,4, BS, Elizabeth Grant1,2, PhD, Lena McCue1,2, PhD, John C. Morris2,3, MD, Jason Hassenstab4,5, PhD, Richard Batla6, PhD, Udo Eichenlaub7, MD, Eugeen Vanmechelen, PhD1
(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (2)Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA (3)Department of Preventive Medicine, Washington University School of Medicine, St. Louis, MO, USA (4) Department of Mathematics, Washington University, St. Louis, MO, USA (5) Roche Diagnostics international, (Rothenz, Switzerland (6) Roche Diagnostics GmbH, Penzberg, Germany (7) Roche Diagnostics Operations, Indianapolis, IN, USA

P70: Sex-specific changes in levels of circulating brain-enriched microRNAs during normal aging and different stages of Alzheimer’s disease
Kira Sheinerman, PhD1, Anne Fagan, PhD2, Elizabeth Grant, PhD3, Aabhas Mathur4, Debra Kessler, RN5, Beth Shaz, MD6, Jon Toledo, MD, PhD6, David Wolk, MD7, John Trojanowski, MD, PhD8, Vladimir Tsvinsky, PhD9, Samuil Umanstky, MD, PhD9
(1) DiamiR Biosciences, Monmouth Junction, NJ, USA (2) Neurology Department, Washington University in St. Louis, MO, USA (3) New York Blood Center, New York, NY USA (4) Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Friday, November 3 and Saturday, November 4

P71: European validation of the PLM-scale, a cerebrospinal fluid biological scale for positive Alzheimer’s disease diagnosis.
Audrey Gabelle1, Sebastiaan Engelborgh2, Koen Poesen3, Panos Alexopoulos4 Martin Vynhalet5, Julien Dumurgier6, Vincent De la Sayette1, Susanna Schraen1, Stéphanie Bomboirs1, Mathilde Sauvée1, Jean-Louis Laplanche1, Jakub Hort1, J. Hugon6, F. Pasquier7, Alzheimer’s Disease Neuroimaging Initiative, Sylvain Lehmann8 and Claire Paquet6
1(Memory Resources and Research Center of Montpellier, Department of Neurology, CHU Gui de Chauliac; and Montpellier University and IRMB, Inserm U1183, Montpellier, France; 2University of Antwerp [UA], Belgium; 3Laboratorium voor Moleculair Neuroradiomarker Leuven; 4Universitat Rostock, Rostock, Germany; 52nd Faculty of Medicine and Motol University Hospital, Czech Republic; 6Clinical Research Center, St. Anne’s University Hospital Brno, Brno, Czech Republic; 7CMRR, Paris Nord Ile-de-France; C.P.; J.H. Inserm UB39; Paris 7- Faculté de médecine Xavier Bichat, France; 8University of Lille Nord de France, Lille University Hospital, INSERM UMR 1172, Lille, France; 9CMRR de Lille, University of Lille Nord de France, France; 10CMRR de Grenoble, Grenoble, France; 11Laboratoire de Biochimie Lariboisière-Fernand Widal Hospital, APHP, University Paris 7-Denis Diderot, Université Paris Descartes, Paris, France; 12Laboratoire de Proteomique, Hospital Biochimie and IFMB, Inserm U1183, Montpellier, France.)

P72: Elecsys® Total-Tau CSF and Elecsys® Phospho-Tau (181P) CSF: novel, fully automated immunoassays for rapid and accurate quantitation of CSF biomarkers for clinical use
Valeria Liftse, PhD1, Ekaterina Manuilova, MSc1, Christian Knop, PhD1, Tobias Selle, PhD1, Werner Kraus, PhD1, Tobias Oelschlaegel, PhD1, Lars Hillringhaus, PhD1
1(1) Roche Diagnostics GmbH, Penzberg, Germany.

P73: Concordance of the Elecsys® β-Amyloid (1-42) [Abeta42] cerebrospinal fluid (CSF), Total-Tau CSF (tTau) and Phospho-Tau (181P) CSF (pTau) immunoassays with amyloid-PET, and their association with clinical progression of Alzheimer’s disease.
Leslie M. Shaw, PhD1, Kaj Blennow, MD, PhD1, Niklas Mattsson, MD PhD1, John Seibyl, MD1, Michal Figurski, PhD1, John Q. Trojanowski, MD, PhD1, Katharina Buch, PhD1, Christina Rabe, PhD1, Udo Eichenlaub, PhD1, Sandra Rutz, PhD1, Monika Widmann, ChTech1, Maryline Simon, PhD1, Oskar Hansson, MD PhD1
1(1) Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA, USA; (2) Clinical Neurochemistry Laboratory, Sahlgrensa University Hospital, Malmö, Sweden; (3) Clinical Memory Research Unit, Lund University, Malmö, Sweden; (4) Institute for Neurodegenerative Disorders, New Haven, CT, USA; (5) Genentech, South San Francisco, USA; (6) Roche Diagnostics GmbH, Penzberg, Germany; (7) Roche Diagnostics, Mannheim, Germany; (8) Roche Diagnostics, Rotkreuz, Switzerland.

P74: Cereznumab pharmacokinetic-pharmacodynamic analysis to describe the increase in total plasma amyloid beta (Aβ) following treatment in patients with mild to moderate Alzheimer’s disease.
Kenta Yoshida1, Anita Moein1, Tobias Bittner2, Lee Honigberg1, Jin Y Jin1, Angelica Quartino1
1(1) Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA, USA; (2) Clinical Neurochemistry Laboratory, Sahlgrensa University Hospital, Malmö, Sweden; (3) Clinical Memory Research Unit, Lund University, Malmö, Sweden; (4) Institute for Neurodegenerative Disorders, New Haven, CT, USA; (5) Genentech, South San Francisco, USA; (6) Roche Diagnostics GmbH, Penzberg, Germany; (7) Roche Diagnostics, Mannheim, Germany; (8) Roche Diagnostics, Rotkreuz, Switzerland.

P75: HGF is Associated with Decreased Subcortical Gray Matter and Hippocampal Volumes on MRI in Young and Middle-Aged Adults
Mehala R. Raman PhD1,2, Jayandra J. Himmel PhD2,3, Sarah C. Conner MPH2,3, Charles DeCarli5 MD, Ramachandran S. Vasan, MD2,3, Alexa Beiser PhD2,3, Sudha Seshadri MD2,3, Claudia L. Satizabal PhD2,3
1(1) Department of Neurology, Boston University School of Medicine, Boston, MA; (2) Framingham Heart Study, Framingham, MA; (3) Department of Biostatistics, Boston University School of Public Health, Boston, MA; (4) Department of Medicine, Boston University School of Medicine, Boston, MA; (5) Department of Neurology, University of California, Davis School of Medicine, Sacramento, CA.

P76: CSF and genetic biomarkers in MCI and AD subjects in J-ADNI for predicting future outcome.
Kazushi Suzuki1, Ryoho Ibara1, Atsushi Iwata1, Taeheki lwatsubo1, Hiroyuki Arai1, Kenji Ishii1, Michio Senda1, Kengo Ito1, Taeheki Ikeuchi1, Ryozo Kuwano1, Hiroshi Matsuda2, for the Japanese ADNI
1(1) The University of Tokyo, Tokyo, Japan; (2) Tohoku University, Sendai, Japan; (3) Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; (4) Institute of Biomedical Research and Innovation, Kobe, Japan; (5) National Center for Geriatrics and Gerontology, Obu, Japan; (6) Niigata University, Niigata, Japan; (7) National Center for Neurology and Psychiatry, Kodaira, Japan.

P77: Concordance between in vivo amyloid imaging and CSF AD biomarkers measured by the automated LUMIPULSE G assay platform
Anne M. Fagan, PhD1, Julia Gray, BS1, Courtney Sutphen, BS1, Amanze Orusakwe, BS1, Gina Jerome, MS1, CJ Traynham, PhD2, Manu Vandalick, MD1, Ziwen Vucetic, MD, PhD2, Ryan Gailey, MBA1, John Lawson, BS, MT (ASCP)1, Brian Gordon, PhD1, Tammie Benzinger, MD, PhD1, David Holtzman, MD1, John C. Morris, MD1
1(1) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; (2) Fujirebio Diagnostics, Malvern, PA, USA; (3) Fujirebio Europe NV, Ghent, Belgium; (4) Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Late Breaking Posters

**LBP39:** Neuroimaging markers of cerebrovascular disease predict cognitive impairment, brain atrophy and dementia in a cohort of community dwelling elders  
Tammy M. Scott PhD, Rafaeque A. Bhadelia MD, and Irwin H. Rosenberg MD  
(1)Jean Mayer USDA Human Nutrition Research Center on Aging; (2)Friedman School of Nutrition Science and Policy; (3)Harvard Medical School

**LBP40:** Measurement of the kinetic behavior of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer’s disease: initial proof-of-concept  
Robert J. Vassar, PhD, Randall J. Bateman, MD, Bruce W. Patterson, PhD, Justyna A. Dobrowolska Zaharia, PhD  
(1)Department of Cell & Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA (2) Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA (3)Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA

**LBP41:** High Serum Levels of Malondialdehyde and 8-OHdG are both Associated with Early Cognitive Impairment in Patients with Acute Ischemic Stroke  
Jincai He, PhD, Zhihua Liu, Yuntao Liu, Xinjie Tu, Huiping Shen, Huihua Qiu, Huijun Chen  
(1) Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

**LBP42:** Analytical Performance of the Lumipulse® G β-Amyloid1-42 assay: Measurement of Within-Lab Precision and CSF Sample Stability.  
Robert A. Rissman, PhD, Louise Monte, MS, Floyd Sarsoza, BS, Amanze Orusakwe, B.S., Manu Vandijck, MD, Ryan Gailey, MBA, John Lawson, B.S., M.T. (ASCP), CJ Traynham, PhD, Zivjena Vuicetic, MD, PhD  
(1) Department of Neurosciences, University of California, San Diego, School of Medicine, (2) Fujiirebio Diagnostics, Malvern, PA, USA, (3) Fujiirebio Europe NV, Ghent, Belgium, (4) Fujiirebio US, Malvern, PA, USA

**LBP43:** Utility of Event Related Potentials in a Memory Disorders Clinic  
Katherine Turk, MD, Cheongmin Suh, Prayerna Uppal, August Price, Ala’a El-Shaar MS, Andrew E. Budson, MD  
(1) Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System (2) Department of Neurology, Boston University School of Medicine (3) William James College

**LBP44:** Analysis of Sex/Genotype Interactions in Baseline EXPEDITION3 Data  
Valerie Bruemmer, MD, Helen M Hochstetler, PharmD, Melissa Anna Maria Pugh, PhD, MS, Sara Kollack-Walter, PhD  
(1) Eli Lilly and Company, Indianapolis, IN, USA

**LBP45:** Central laboratory validation and performance assessment of new automated Ab1-42 and Total tau immunoassays  
Didier Pitsi, PharmD, PhD, Joachim Vandroemme, PhD, Walter Hofer, BSc, Els Decoster, PhD, Astrid Coppens, PharmD, DCP  
(1) BARC Global Central Laboratory, Ghent, Belgium (2) CRI Medical Laboratory, Ghent, Belgium (3) CRI Medical Laboratory at the time of these experiments, Ghent, Belgium

**LBP46:** Application of the revised diagnostic criteria for the early stages of Alzheimer’s disease to the LipiDiDiet study population  
Tobias Hartmann, PhD, Kaj Blennow, PhD, Pieter Jelle Visser, PhD, Alina Solomon, MD, PhD, Suzanne B Hendrix, PhD, Miia Kiivelä, MD, PhD, Hilthta Soininen, MD, PhD on behalf of the LipiDiDiet clinical study group  
(1) Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany (2) Department of Experimental Neurology, Saarland University, Homburg, Germany (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden (4) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden (5) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands (6) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands (7) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland (8) Department of Clinical Geriatrics, NIVS, Karolinska Institute, Huddinge, Sweden (9) Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden (10) Pentara Corporation, Salt Lake City, UT, USA (11) Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland
CTAD 2017

Friday, November 3 and Saturday, November 4

Theme 5. Clinical trials: Cognitive and functional endpoints

P78: Short-term repeat cognitive testing and its relationship to hippocampal volumes in older adults
Kevin Duff PhD1, Jeff Anderson MD PhD2, Atul Mallhi MD PhD2, Kayla R. Suhrie BS1, Bonnie C. Allred Dalley BSI, Taylor J. Atkinson BA1, John M. Hoffman MD & Keefe, PhD

(1) University of Utah, Salt Lake City, UT, USA (2) Department of Radiology, University of Utah, Salt Lake City, UT, USA (3) Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

P79: Development and validation of a short version of the Amsterdam IADL Questionnaire: a potential functional outcome measure for clinical trials
Roos J Jutten, MSc1, Barnabas M. Weerts MSc1, Kevin Duff PhD1, Philip Scheltens, MD, PhD2, Sietse AM Sijtsma, PhD2

(1) Alzheimer Center, Department of Neurology, UvA University Medical Center, Amsterdam, The Netherlands (2) Department of Epidemiology & Biostatistics, Amsterdam Public Health research institute, VU University Medical Center, Amsterdam, The Netherlands (3) Alzheimer Center Rotterdam, Erasmus Medical Center, Rotterdam, The Netherlands.

P80: Expanding the Brief Assessment of Cognition (BAC-App) for assessment of cognition in aging: Preliminary normative data and sensitivity to subjective cognitive decline
Alexandra S. Atkins, PhD1, Anzalee Khan PhD2, Joan Stroescu PhD1, Kathleen A. Welsh-Bohmer PhD1, Brenda L. Plassman PhD1, Christopher Randolph, PhD1, John Harrison PhD1,6, Adam W. Vaught, PhD1, Dañela Balentin, MA1, Dean Holbert, BA1, Caty Hooks, MSW1, and Richard S.E. Keefe, PhD1,7

(1) NeuroCog Trials, Durham, NC, USA; (2) University of Pennsylvania, Philadelphia, PA, USA; (3) Duke University School of Medicine, Durham, NC, USA; (4) Loyola University Medical Center, Maywood, IL, USA; (5) Alzheimer Center, VUmc, Amsterdam, The Netherlands; (6) Cognetivity, Inc., Denver, CO, USA; (7) Duke University Medical Center, Durham, NC, USA

P81: Extracting digital biomarkers of sleep from 3-axis accelerometry using Deep Learning
Robin Wolz, PhD1, Janet Munro, MBBS MPhil MRCPsych, Ricardo Guerrero, PhD2, Dereh Hill, PhD1, Yves Dauvilliers, MD PhD3

(1) Imperial College Festival of Sleep, London, UK; (2) Imperial College London, London, UK; (3) Sleep Unit, Department of Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM 1061, France

P82: Assessing the Potential of Patient Dependence Levels as a Treatment Outcome – Insights from EXPEDITION3
Daniel F. Ball, DrPH1, J. Scott Andrews, PharmD1, Wenyu Ye, PhD1, Ann M. Hale, MD1, Helen M. Hochstetler, PharmD1, Brandy R. Matthews, MD1, Kristin K. Wrobleski, PhD1

(1) Eli Lilly and Company, Indianapolis, IN

P83: Maximum Walking Speed, Physical Activity, and AD Biomarkers: Results from the Harvard Aging Brain Study
Dylan R. Kim, MPH1, Ruth Buchley, PhD1,4,6, Bernard Hanseewu1, Kathleen M. Klein1, Dorene M. Rentz, PsyD2, Reisa A. Sperling, MD MMS12,3, Keith A. Johnson, MD2,3

(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA (2) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; (3) Harvard Medical School, Boston, MA, USA; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

P84: Providing Culturally Sensitive Training and Monitoring to Clinicians Administering Functional Assessments in Dementia Global Trials
Magdalena Perez1, Julie Marsh1, Chris Brady1, Patricia Belchior2, Isabelle Gelinas3, Christelle Giroudet4, Caroline Anfray4, Shuhong Zhao1

(1) InVivo Health, Somerset, New Jersey, United States; (2) Centre de Recherche Universitaire de Geriatrie de Montreal, McGill University, Montreal, Quebec, Canada; (3) Centre de Recherche Interdisciplinaire en Readaptation du Montreal, McGill University, (4) MAP, Lyon, France

P85: Gaining Efficiencies in Prevention Trial Design: Sample Size Projections across Categorical and Continuous Cognitive Endpoints
Rebecca L. Koscib1, Erin M. Jonaitis, PhD1, Bruce P. Herrmann, PhD1, J. Scott Andrews, PharmD1,4,6, Brandy R. Matthews, MD1, Cindy M. Carlsson, MD, MS3,1, Sterling C. Johnson, PhD1

(1) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; (2) Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; (3) Geriatric Research Education and Clinical Center, Wm. S. Middleton Veterans Hospital, USA; Madison WI, USA
CTAD 2017

POSTER PRESENTATIONS

Friday, November 3 and Saturday, November 4

P86: LONGITUDINAL DATA MODELING: AN APPROACH TO ENABLE THE PREDICTION OF BIOMARKER TRAJECTORIES FOR ALZHEIMER’S DISEASE

Meemansa Sood, M.Sc.1,2, Sven Hodapp, M.Sc1, Anandhi Iyappan, M.Sc1,2, Marc Jacobs, PhD1 Prof. Martin Hofmann-Apitius 1,2
1) Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sanitär, Augustin, Germany (2) Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn-Aachen International Center for IT, Bonn, Germany.

Late Breaking Posters

LBP47: Exploring the Utility of the Digital Clock Drawing Test in Capturing Subtle Cognitive Changes and Biomarker Evidence at the Preclinical Stage of Alzheimer’s Disease

Dorene M. Rentz, PsyD1,2, Kathryn V. Papp, PhD1,2, Irina Orlovsky, MA2, William Souillard-Mandar4, Dana Penney, PhD3,4, Randall Davis, PhD3, Keith A. Johnson, MD1,2,3
1) Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA (2) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (3) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (4) Department of Neurology, Lahey Hospital and Medical Center, Burlington, MA, USA (5) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA

LBP48: Clinical meaningfulness of Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) scale in relation to goal attainment in participants on cholinesterase inhibitors

Susan E. Howlett, PhD1,2, Justin Stanley, BSc1, Helen Wong, MSc1, Arnold Mitnitski, PhD1,2 Kenneth Rockwood, MD1,2
1) DCI Clinical Inc., Halifax, NS, Canada (2) Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada (3) Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

LBP49: Assessment of iADL functioning in individuals with subjective cognitive decline using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)

Alexandra S. Atkins, PhD1, Lauren Trottier, MS, CSP1, Katherine Kruczak, MS1, Pamela Voccia1, Katey Smith, MS, CSP1, Craig Curtis, MD1, Ira Goodman, MD1
1)  Compass Research – Bioclinica, Orlando, FL, USA

Theme 6. Cognitive assessment and clinical trials

P87: Use of the CVLT-II as a pre-screening tool to reduce screen fails in MCI clinical trials.

Mariette Caial, PhD1, Lauren Trottier, MS, CSP1, Katherine Kruczak, MS1, Pamela Voccia1, Katey Smith, MS, CSP1, Craig Curtis, MD1, Ira Goodman, MD1
1)  Compass Research – Bioclinica, Orlando, FL, USA

P88: Enriching Participant Eligibility for Early AD Clinical Trials through Computerized Pre-Screening for Episodic Memory Deficit

Kenton Zavit, Rosemary Abbott, Francesca Cormach, Pasquale Dente, Jennifer H Barnett
Cambridge Cognition, Cambridge, UK

P89: An Objective Clinical Vocabulary for the Temporal Unfolding of AD Biomarkers: Stages of Objective Memory Impairment

Ellen Grober, PhD1, Amy E. Veroff, PhD2
1) Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA (2) Consultant, Bethesda, Maryland, USA

P90: Object and scene memory are differentially associated with CSF markers of Alzheimer’s Disease and MRI volumetry

David Berron1,2, Hartmut Schützel, Arturo Cardenas-Blanco1, Klaus Flessbach1, Michael Wagner1, Aninka Spotte1, Martin Reuter1,2, Stefanie Reuter1,2, Katarina Bürger4,5, Oliver Peters1,2, Peter Nestor1,2, Josef Priller1,5, Jens Wiltfang1,5, Christoph Laske1,5, Frank Jessen1,2, Emrah Düzel1,3, and the DELCODE consortium
1) Institute of Cognitive Neurology and Dementia Research, Otto von Guericke University Magdeburg, Germany (2) German Center for Neurodegenerative Diseases Magdeburg, Germany (3) Institute of Cognitive Neuroscience, University College London, United Kingdom (4) Department of Psychiatry, University Hospital Bonn, Bonn, Germany (5) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany (6) Department of Psychosomatic Medicine, University Medicine Rostock, Germany (7) German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany (8) Department of Psychiatry, University of Cologne, Cologne, Germany (9) Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU), Munich, Germany (10) German Center for Neurodegenerative Diseases (DZNE), Munich, Germany (11) Department of Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany (12) German Center for Neurodegenerative Diseases (DZNE) Berlin, Germany (13) Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany (14) German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany (15) Department of Psychology and Psychotherapy, Eberhard Karls University Tübingen, Tübingen, Germany (16) German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany (17) Department of Radiology, Harvard Medical School, Boston, USA (18) Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, USA
**Friday, November 3 and Saturday, November 4**

**P91:** Effectiveness of Rater Training and Data Surveillance in Alzheimer’s Disease (AD) Clinical Trials  
Rolana Avrumson, MS1, Melissa A. Carbo, MS2, Henry J. Riordan, PhD1, Michael F. Murphy, M.D., PhD2, Neal R. Cutler, M.D.1, Michael F. Murphy, M.D., PhD2, Neal R. Cutler, M.D.1  
(1) Worldwide Clinical Trials, Beverly Hills, CA (2) Worldwide Clinical Trials, King of Prussia, PA

**P92:** Diagnostic value of a cognitive battery for assessing cognitive decline  
A. Nidos1, D. Kasselimis2, K. Zavitz3, F. Cormack1  
(1) Neurological Clinic – Department of Neuropsychology, Metropolitan Hospital (2) 1st Neurology Department, National and Kapodistrian University of Athens (3) Cambridge Cognition

**Late Breaking Posters**

**LBP50:** Breadth and Depth of Working Memory and Executive Function Impairment in Mild Cognitive Impairment  
Terry E. Goldberg, PhD1 and Jesus Gomar, PhD2  
(1)Geniatric Psychiatry, Columbia University Medical Center, NYC, NY (2)Liswin Zucker Alzheimer’s Center, Manhasset, NY

**LBP51:** The Early AD/ MCI Alzheimer’s Cognitive Composite (EMACC): Development and preliminary validation across four longitudinal cohorts of a cognitive endpoint for clinical trials in the MCI and Early AD stage of disease.  
Judith Jaeger, PhD2, Clint Hagen, MS1, Hennilt Loft, PhD1, Yen Ying Lim, PhD1, Andrew Aschenbrenner, PhD1, Marta Segerdahl, MD, PhD1, Gary Tong, MD, PhD1, Michelle Mielke, PhD1, Jason Hassenstab1, PhD, Niluthi Stricker, PhD1  
(1)Albert Einstein College of Medicine, Bronx, NY and Cognition Metrics, LLC, Wilmington, DE, USA (2) Mayo Clinic, Rochester, MN, USA (3) H Lundbeck A/S, Valley, Denmark (4) The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia (5) Washington University in St. Louis, St. Louis, MO

**LBP52:** A comparison of in-person and web-based computerised cognitive testing using CANTAB  
Francesca Cormack1, Rosa Backx1, Jack Cotter1, Nich Taptitili1, Lucie de Cock1, Kenton Zavitz1, Jennifer H. Barnett1  
(1) Cambridge Cognition, Cambridge, UK (2) Department of Psychiatry, University of Cambridge, UK

**LBP53:** Automated voice-based testing: applications in recruitment of patients in clinical trials  
Nich Taptitili1, Francesca Cormack2, Jennifer H Barnett1  
(1) Cambridge Cognition, Cambridge, UK (2) Department of Psychiatry, University of Cambridge, UK

**LBP54:** Use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer’s disease in the Eisai elenbecestat MissionAD phase 3 clinical trials  
Bruce Albala, PhD1, Michelle Gee, PhD2, Adrian Schembri, PsyD1, Paul Maruff, PhD1  
(1) Eisai Inc., Woodcliff Lake, New Jersey, USA (2) Eisai Ltd, Hatfield, UK (3) Cogstate Ltd, Melbourne, Australia

**LBP55:** Assessing risk factors for cognitive impairment in patients with diabetes  
Martin Rakusa, MD, PhD1, Matej Rakusa, MD2, Miro Cokolic, MD2  
1Department of Endocrinology and Diabetes University Medical Centre Maribor, Maribor, Slovenia, 2Department of Neurology University Medical Centre Maribor, Maribor, Slovenia

**LBP56:** PRELIMINARY FINDINGS OF APTEST: A PRESCREENING TOOL DEMONSTRATING INITIAL PREDICTIVE AND DIAGNOSTIC IMPLICATIONS.  
Pamela Voccia, Ed.S.1, Katherine Kruczelt, M.S.1, Joy Ketren, M.S.1, Jennifer Cody, B.S.1, Nichole Stiirvin, B.A.1  
(1) Bioclinica Research, The Villages, Florida, USA

**LBP57:** Psychometric Properties of the Imprint Eye Tracking Memory Assessment: Internal, Test-Retest and Alternate Forms Reliability  
Nicholas T. Bott, PsyD2, Alex Lange, MS1, Robert Cosgriff, MS1, Paul Clopton, MS1, Beth Buffalo, PhD2, Stuart Zola, PhD3, Claudia Y. Santos-B6, Peter Snyder, PhD2  
(1) Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA (2) Rancho Los Amigos National Medical Center, Downey, California, USA (3) University of California San Diego School of Medicine, San Diego, California, USA (4) University of Washington, Seattle, Washington, USA (5) Emyr University Office of the Provost, Atlanta, Georgia, USA (6) Interdisciplinary Neurosciences Program, University of Rhode Island, Kingston, RI, USA (7) Lifespan Clinical Research Center, Rhode Island Hospital, Providence, RI, USA (8) Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA

**LBP58:** Utility of the International Shopping List Test for detection of memory impairment associated with prodromal and early Alzheimer’s disease in clinical trials  
Paul Maruff, PhD1, Adrian Schembri, PsyD1, Shau Yu Lynch, PhD1, Bruce Albala, PhD1  
(1) Cogstate Ltd, Melbourne, Australia (2) Eisai Inc., Woodcliff Lake, New Jersey, USA
LBP59: DCTclock metrics correlate with neuroimaging biomarkers among those with AD genetic risk
Braydon Schable, William Souillard-Mandar, Randall Davis, Rhoda Au, Dana Penney
(1) Digital Cognition Technologies, Inc., Waltham, MA, USA, (2) MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA (3) Boston University School of Medicine and Public Health, Boston, MA, USA, (4) Lahey Hospital and Medical Center, Burlington, MA, USA

Theme 7. Behavioral disorders and clinical trials

P93: Lumateperone (ITI-007), a novel drug in development for the Treatment of Agitation in Patients with Dementia, Including Alzheimer’s Disease: Rationale and Clinical Trial Design
Robert Davis Ph.D.1, Kimberly Vanover Ph.D.1, Cedric O’Gorman MD1, Jelena Saillard1, Michal Weingart Ph.D.1, Sharon Mates Ph.D.1

P94: Alzheimer’s Disease Cooperative Study (ADCS) Multicenter Trial: Prazosin for Agitation in Alzheimer’s Disease (PEACE-AD)
Elaine R. Peskind, MD1,2, Murray A. Raskind, MD1,2, Howard Feldman, MD, FRCP1,2, for the Alzheimer’s Disease Cooperative Study
(1)VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center (MIRECC), Seattle-American Lake, WA, USA (2)University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA (3) Alzheimer’s Disease Cooperative Study, San Diego, CA, USA (4) University of California, San Diego, Department of Neurosciences, San Diego, CA, USA Alzheimer’s Disease Cooperative Study (ADCS)

P95: Neuropsychiatric symptoms and the risk of conversion to dementia among MCI subjects
Maria Soto, MD, PhD1, Simon Dietlin, MD1, Vera Kiyasova PhD2, Maria Pueyo, MD, PhD2, Adelaide de Mauléon, MD1, Julien Deltrieu, MD1, Pierre Jean Ousset, MD1, Bruno Vellas, MD, PhD1
(1) Gerontology, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, France (2) Institut de Recherches Internationales Servier, Suresnes, France

P96: Natural History, Epidemiology, Neurobiology, Burden, and Unmet Needs of Agitation in Alzheimer’s Disease: Where are we now? A Systematic Review
Chuidian M1, Waterman F1, Bird S1, De Jong-Laird A1, Baker R1, Megerian T1
(1)Avanir Pharmaceuticals Inc, Aliso Viejo, CA (2) Xcenda, Palm Harbor, Fl (3) Otsuka Pharmaceutical Europe Ltd. (OPEL), Gallions, Wexham Springs (4) Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC), Princeton, NJ

Late Breaking Posters

LBP60: Donepezil treatment in patients with depression and cognitive impairment on stable antidepressant treatment: a randomized controlled trial
Davangere P. Devanand, MD1, Gregory H. Pelton, MD2, Kristina D’Antonio, MSW2, Adam Ciarleglio, PhD3, Jennifer Scodes, MS4, Howard Andrews, PhD5, Julia Lumsford, MD1, John L. Beyer, MD8, Jeffrey R. Petrella, MD6, Joel Sneed, PhD4, P. Murali Doraiswamy, MD11
(1)Pfizer; (2)St. Luke’s & Roosevelt Hospital Center, New York, NY; (3)Biostatistics, Department of Psychiatry, Columbia University, New York, NY; (4)Biostatistics, Department of Psychiatry, University of Washington, Seattle, WA; (5)Biostatistics, Department of Psychology, Columbia University, New York, NY; (6)Biostatistics, Department of Psychiatry, Columbia University, New York, NY; (7)Biostatistics, Department of Psychiatry, University of Washington, Seattle, WA; (8)Department of Psychiatry, Duke University, Durham, NC, USA; (9)Department of Radiology, Duke University, Durham, NC, USA; (10)Department of Psychology, Queens College, City University of New York, New York, NY, USA; (11)Department of Psychiatry, Duke University, Durham, NC, USA

LBP61: Memantine ER With an AChEI Improves Individual SIB Scores Compared With AChEI Alone: Post Hoc Analyses From a Randomized, Double-blind, Placebo-controlled Study
George Grossberg, MD1, Ken Kramer, PhD2, Suzanne Hendrix, PhD3, Noel Ellison, MS4, Majid Kerolous, PharmD, MPH2
(1) Saint Louis University, Saint Louis, MO, USA (2) Allergan, Jersey City, NJ, USA (3) Pentara Corporation, Salt Lake City, UT, USA

LBP62: Using Radio Signal-based Sensing and Machine Learning for Continuous Longitudinal Monitoring of Behavioral Symptoms in Dementia: A Pilot Case Study
Ipsit Vahia, MD1, Zachary Kabelac, MEng2, Chen-Yu Hsu, MS3, Rumen Hristov, MEng2, Patrick Monette, BS1, David Harper, PhD1, William McGrory, LCWS3, Brent Forester, MD1, Dina Katabi, PhD2
(1) Division of Geriatric Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA, USA; (2) Computer Science and Artificial Intelligence Lab (CSAIL), Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; (3) Robbie’s Place Assisted Living, Marlborough, MA
Friday, November 3 and Saturday, November 4

Theme 8. Health economics and clinical trials

P97: Cost of illness and economic burden of early Alzheimer’s disease: a systematic review
Richard Lawson, MSc; Weiguang Xue, MSc; Adam Lloyd, MPhip; Christina-Jane Crossman-Barnes, MSc; Rebekah Fong, MSc
(1) AstraZeneca, US (2) QuintilesIMS, UK (3) University of East Anglia, UK

P98: Challenges in Optimising Real World Evidence for Alzheimer’s Disease
Catherine Reed, PhD; Frederic de Reydet de Vulpillieres, MSc; John Gallacher, PhD; and the ROADMAP consortium
(1) Eli Lilly and Company Limited, Windlesham, UK (2) Novartis Pharma AG, Basel, Switzerland (3) University of Oxford, UK

P99: Dependence Scale to Assess the Cost-Consequences of Alzheimer’s Disease Treatments
Joshua A. Roth, PhD, MHA; Joshua T. Cohen, PhD; Peter J. Neumann, ScD; Carolyn W. Zhu, PhD; Yaakov Stern, PhD; Sean D. Sullivan, PhD
(1) Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (2) Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA (3) Department of Genetics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA (4) Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA (5) Department of Pharmacy, University of Washington, Seattle, WA, USA

Late Breaking Posters

LBP63: Review of clinical guidelines on use of antipsychotic drugs in the treatment of behavioral symptoms in dementia and their impact on patient outcomes
Myrline Sanon Aigbogun, MPH; Milena Anatchkova, PhD; Anne Brooks, BS; Laura Swett, PhD; Ann Hartry, PhD; Ruth A. Duffy, PhD; Ross A. Baker, PhD

LBP64: The Natural Progression of Agitation in Alzheimer’s Disease/Dementia: A Systematic Literature Review
Milena Anatchkova, PhD; Anne Brooks, BS; Laura Swett, PhD; Ann Hartry, PhD; Ruth A. Duffy, PhD; Ross A. Baker, PhD; Myrline Sanon Aigbogun, MPH

Theme 9. Epidemiology and clinical trials

P100: Prevalence and progression of preclinical and prodromal AD among non-demented persons in a population-based setting.
Rosebud O. Roberts, MB ChB, MS; Jeremiah A. Ahre, MPH; Walter K. Kremer, PhD3, Maria Vassilaki, MD, PhD; Michelle M. Mielke, PhD; David S. Knopman, MD2, Yonas E. Geda, MD, MSc1,4, Preciosa Coloma, MD, PhD5, Barbara Schaubie, MD, PhD6, Val J. Lowe, MD, PhD7, Clifford R. Jack Jr, MD7, Ronald C. Petersen, PhD, MD12
(1) Department of Health Sciences Research, Mayo Clinic, Rochester, MN (2) Department of Neuroscience, Mayo Clinic, Rochester, MN (3) Department of Biomedical Sciences, Mayo Clinic, Rochester, MN (4) Departments of Psychiatry and Neurology, Mayo Clinic, Scottsdale, AZ (5) Real World Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland (6) Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland (7) Department of Radiology, Mayo Clinic, Rochester, MN

P101: Lipophilic Versus Hydrophilic Statin Exposure and Post-Mortem Neuropathological Findings in the NACC Autopsy Cohort
Aaron M. Koenig MD; Jing Qian PhD; Rebecca A. Betensky PhD; Steven E. Arnold MD
(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA (2) Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA (3) Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Friday, November 3 and Saturday, November 4

P102: The longitudinal association of glycemic control based on glycemic target of the JDS/JGS joint committee with cognitive and ADL decline in patients with MCI and AD.
Taiki Sugimoto, RPT, MSc1,2,3,4, Tatsuki Saito, MD, PhD1,2,3,4, Taiji Kimura, RD, MSc1,2,3,4, Taiji Sugimoto, RPT, MSc1,2,3,4, Rei Ono, RPT, MPH, PhD1, Naoki Saji, MD, PhD1, Shumpei Niida, PhD1, Kenji Toba, MD, PhD1
(1) Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan (2) Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan (3) Department of Community Health Sciences, Kobe University, Graduate School of Health Sciences, Kobe, Japan (4) National Health Service, Japan Society for the Promotion of Science, Tokyo, Japan (5) Department of Cognitive and Behavioral Science, Nagoya University Graduate School of Medicine, Nagoya, Japan

P103: Clinical Attributes and Disease Progression among Patients with Mild Cognitive Impairment Associated with Alzheimer’s disease: Findings from the National Alzheimer’s Coordinating Center
J. Scott Andrews, PharmD1,2,3 Urvi Desai, PhD,2 Noam Y. Kirson, PhD,2 Miriam Zichlin, MPH,2 Sophie Schonfeld, BA,2 Daniel E. Ball, DrPH,1 Colin Green, PhD3
(1) Eli Lilly and Company, Indianapolis, IN (2) Analysis Group, Inc., Boston, MA (3) University of Exeter, Exeter, UK

P104: The association between body mass index and cognitive decline in patients with small vessel disease -preliminary study
Hae-Eun Shin, Seong-Hoon Kim, Si Baek Lee, Jung-Wook Park, The Catholic University of Korea, Uijeongbu, South Korea

P105: Nutritional status in patients with MCI, AD and DLB and its clinical meaning for dementia prevention and care.
Ai Kimura, RD, MSc1,2,3,4 Takashi Saito, MD, PhD1,2,3 Taiji Sugimoto, RPT, MSc1,2,3,4, Kazuya Kitamori, RD, PhD1, Naoki Saji, MD, PhD1, Shumpei Niida, PhD1, Kenji Toba, MD, PhD1
(1) Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan (2) Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan (3) Department of Cognitive and Behavioral Science, Nagoya University Graduate School of Medicine, Nagoya, Japan (4) Department of Community Health Sciences, Kobe University, Graduate School of Health Sciences, Kobe, Japan (5) Japan Society for the Promotion of Science, Tokyo, Japan (6) College of Human Life and Environment, Kinjo Gakuin University, Nagoya, Japan

P106: Optimizing Dietary Intervention Studies of Modifiable Risk Factors and Comorbidities for Late Onset Alzheimer’s Disease
Feng-Yen Li, PhD1 and Ann Lam, PhD2
(1) Physicians Committee for Responsible Medicine, Washington, DC, USA (2) Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA

P107: Is the time right to capitalise on emergence of Lifetime and Lifestyle Alzheimer’s disease Related Factors as Determinants of pre-disease Neurocognitive Performance? Cross-sectional evidence from the CHARIOT PRO Main Study
Chinedu T Udoh-Momoh, PhD1,2 Bowen Su MD1,3, Geraint J Price, DClinPsych1,2, David Muller, PhD1,2, Darina Bassil, MPH1, Catherine Robb, MSc1,2, Heather Ward, PhD1,2, Michael T. Ropacki, PhD1,2, Robert Pernecky, MD1,2, Ioanna Tzoulaki, PhD1,2, Leifos T Middleton, MD1,2
(1) Imperial College London, London, United Kingdom (2) Ludwig Maximilians Universitat, Munich, Germany (3) Janssen Research and Development, Fremont, CA, USA (4) Loma Linda University School of Medicine, Loma Linda, CA, USA (5) MedAvante, Inc., Hamilton, NJ, USA

P108: Clinical trial recruitment rate from a patient data base in an academic geriatric center
Daniel G. Gámez Treviño, Blanca I. González García, Patricia A. Guerrero Garza, Ricardo Salinas Martínez
Geriatric Services, “Dr. Jose Eleuterio Gonzalez” University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nueva León, México.
Friday, November 3 and Saturday, November 4

Theme 10. Clinical Trials: Animal Models


Aruna SHARMA1, José V LAFUENTE2, Dafin F MURESANU3, Rudy J CASTELLANI4, Mark A SMITH5, Ranjana PATNAIK6, Z Yuan TIAN7, Asya OZKIZILCIK2, Herbert MÖSSLER8, Hari S SHARMA9

1) International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Uppsala University Hospital, Uppsala University, Uppsala, Sweden (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; a RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania (4) University of Maryland, Baltimore, MD, USA (5) Case Western Reserve Medical University, Cleveland, OH, USA (6) School of Biomedical Engineering, Indian Institute of technology, Banaras Hindu University, Varanasi, India (7) Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA (8) Ever NeuroPharma, Oberburgau, Austria

PIO10: Nanodelivery of Cerebrolysin potentiates histamine antibodies and histaminergic H3 and H4 receptor modulation induced reduction in brain pathologies in Alzheimer’s disease.

Hari Shantner SHARMA1, José V LAFUENTE2, Dafin F MURESANU3, Rudy J CASTELLANI4, Mark A SMITH5, Ranjana PATNAIK6, Z Yuan TIAN7, Asya OZKIZILCIK2, Stephen D SKAPER6, Herbert MÖSSLER8, Aruna SHARMA9

1) International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; a RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania (4) University of Maryland, Baltimore, MD, USA (5) Case Western Reserve Medical University, Cleveland, OH, USA (6) School of Biomedical Engineering, Indian Institute of technology, Banaras Hindu University, Varanasi, India (7) Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, (8) University of Padua, Faculty of Medicine, Padua, Italy, (9) Ever NeuroPharma, Oberburgau, Austria

PIO11: Can the use of approved imaging compounds also be used a therapy in Alzheimer’s Dementia

James Fontanesi MD1; Daniel B Michael MD 1; Alaa Hanna MD1; Michael Maddens MD1; Prakhes Chiniya1; Giovanni Fontanesi2; Thomas Wilson1; Alvaro Martinez MD3; Katie Buelow1; Barbara Pruetz1; George D Wilson Ph.D1

1) William Beaumont Health Systems (2) Oakland University, Rochester , Mi, USA (3) 21st Century Oncology, Farmington Hills, Mi, USA

PIO12: Inhibition of Caspase-1 as a novel treatment against age-dependent cognitive decline and Alzheimer Disease

Andrea C. LeBlanc1, Joseph Flores1

1) Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada (2) Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada

PIO13: Combination radiation techniques may play a role in the treatment of Alzheimer’s Dementia

James Fontanesi MD1; Daniel B Michael MD 1; Michael Maddens1; Alaa Hanna MD1; Thomas G Wilson BS1; Giovanni Fontanesi2; Prakhes Chiniya1; Alvaro Martinez MD3; Katie Buelow1; George D Wilson Ph.D1

1) William Beaumont Health Systems (2) Oakland University, Rochester , Mi, USA (3) 21st Century Oncology, Farmington Hills, Mi, USA

Late Breaking Posters


Ramatrishna Nirogi, PhD1, Vijay Benade MS1, Renny Abraham, PhD1, Gopinadh Bhyrapuneni, PhD1, Jyothsna Ravula, MS1, Koteshwara Mudigonda, PhD1, Devender Reddy Ajiala,PhD1, Ramasasy Kambhampati, PhD1, Anil Shinde, Ph.D1 and Venkat Jasti MS1

1) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

LBP14: The PDE4-inhibitor roflumilast improves memory: findings from a translational perspective

Arian Blomholm, PhD, Wim Riedel, PhD, Marlies Van Duinen, PhD, Ante Sambeth, PhD, Plim Hechman, PhD, Max Tsai, PhD, Gezim Lahi, PhD, Tolga Uz, MD, PhD, Jos Prichaerts, PhD

1) Department of Neuropsychology and Psychopharmacology, Maastricht University, Maastricht, The Netherlands (2) Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands (3) Taheeda Development Center, Taheeda, Deerfield, USA (4) Taheeda Pharmaceuticals International, Taheeda, Zurich, Switzerland
CTAD 2017 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors
General Information

Conference Venue

Boston Park Plaza
50 Park Plaza at Arlington Street,
Boston, MA 02116
USA

Breakfast for people staying at the Boston Park Plaza in the CTAD Block: Information will be handed to you upon check-in regarding breakfast location for each day of your stay.

Registration Information (no onsite registration)

Pre-registration:
Avoid the rush and come pick-up your conference materials on Wednesday, November 1 starting at 1pm.

Registration desk opening hours:
Thursday, November 2 from 7:30 am to 6 pm
Friday, November 3 from 7:30 am to 5:30 pm
Saturday, November 4 from 7:30 am to 4:30 pm
Conference Room:
All sessions will be held in Grand Ballroom A and B (Mezzanine level)

Coffee Breaks and Poster Sessions:
Georgian Room and Ballroom Foyer (Mezzanine level)

Lunches*:
(only for attendees who purchased the lunch package) in ABC rooms (Mezzanine Level) please present your badge at the entrance.
*No possibility of buying lunches onsite

Speaker Ready Room - Preview room - Hours of Operation
• Wednesday, November 1: 1 pm – 6 pm
• Thursday, November 2: 7:30 am – 6 pm
• Friday, November 3: 7:30 am – 6 pm
• Saturday, November 4: 7:30 am – 4 pm

POSTER SESSIONS
All the necessary material will be available onsite to display your poster

Wednesday, November 1 and Thursday, November 2
Poster set-up: Wednesday, November 1 starting at 1pm
Poster take-down: Thursday, November 2 no later than 6pm

Theme 1. Clinical trials: Methodology - P1 to P25 and LBPI to LBPI2
Theme 2. Clinical trials: Results - P26 to P42 and LBPI5 to LBPI32
Theme 11. New therapies and clinical trials - P114 to P129 and LBPI5 to LBPI24

Friday, November 3 and Saturday, November 4
Poster set-up: Friday, November 3 starting at 7:30 am
Poster take-down: Saturday, November 4 no later than 5pm

Theme 3. Clinical trials: Imaging - P43 to P55 and LBPI5 to LBPI38
Theme 4. Clinical trials: Biomarkers including plasma - P56 to P77 and LBPI9 to LBPI6
Theme 5. Clinical trials: Cognitive and functional endpoints - P78 to P86 and LBPI47 to LBPI49
Theme 6. Cognitive assessment and clinical trials - P87 to P92 and LBPI50 to LBPI59
Theme 7. Behavioral disorders and clinical trials - P93 to P96 and LBPI60 to LBPI62
Theme 8. Health economics and clinical trials - P97 to P99 and LBPI63 to LBPI64
Theme 9. Epidemiology and clinical trials - P100 to P108
Theme 10. Clinical Trials: Animal Models - P109 to P113 and LBPI3 to LBPI4
Conference Mobile App

CTAD 2017 has its own Mobile App!

The App will be available for download on October 28, 2017 on the Apple App Store and Google Play (search CTAD17) to be used on your mobile phone but also on larger devices like an iPad or a desktop.

The conference is right at your fingertips: discover the program, read the abstracts, learn more about our speakers, network with other participants and so much more!

Get in touch

CTAD BOSTON 2017
CTAD Congress
Phone: +33 4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTAD2017 CTAD Alzheimer CTAD Conference

#CTAD17

www.ctad-alzheimer.com
October 24-27, 2018
BARCELONA

www.ctad-alzheimer.com